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Various advantages result even from the publication of opinions; for 
though we are very liable to error in forming them, yet their promulga-
tion, by exciting investigation, and pointing out the deficiencies of our 
information, cannot be otherwise than useful in the promotion of science. 
John Abernethy [1764 - 1831] 
ii 
In this research the statistical analyses and recommendations arising from 
these analyses have been performed in consultation with the Institute for 
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INTRODUCTION 
Research is fundamentally a state of mind involving continual reexamination 
of the doctrines and axioms upon which current thought and action are 
based. It is, therefore, critical of existing practices. 
Theobald Smith [1859 - 1934] 
Almost a century has elapsed since the antigen-antibody interaction was first 
recognised as the basis of an immune response (Ehrlich, 1897). However, it was only 
in the 1930s, with the development of improved technologies that this concept was 
better understood, and led to the discovery of the amazing diversity and specificity 
of antibody molecules (Landsteiner, 1933). Theoretically, it is possible to make 
antibodies to a variety of biological substances and other chemicals, and therefore 
they are ideally suited as specific recognition elements to be used for analytical, 
cytological, functional, therapeutic and biochemical purposes. 
The development of the radioimmunoassay (RIA) thirty five years ago, revolutionised 
research in many areas of clinical and scientific investigation. This technique evolved 
rapidly from the discovery made by Berson et al. in 1956 that antibodies to insulin 
could be detected in patients treated with this hormone, by measuring the binding of 
radiolabeled insulin to these antibodies. 
Although in the past RIAs have been the most important assay system employing 
antibody and labelled tracer, the limitation was that reliance had to be placed on the 
chance development of a good polyclonal antibody. These shortcomings stimulated 
the search for monospecific antibodies of reproducible quality and sufficient quantity. 
The development and introduction of monoclonal antibody technology brought about 
a revolution in immune serology (Kohler and Milstein, 1975). Establishment of 
immortal cell lines which contained the genetic elements of antibody-producing cells 
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was achieved by fusion between a myeloma cell line and spleen cells from an 
immunised donor. The resulting hybrids had the essential properties of both parents, 
namely, permanent growth and a high capacity for the synthesis and secretion of 
immunoglobulins, normally characteristics of plasmacytomas, together with the 
genetic elements defining a specific antibody. 
Gestational trophoblastic disease (GTD) is a neoplastic condition of the trophoblast 
and occurs as molar pregnancy in a benign or invasive form, or as choriocarcinoma 
in a malignant form. Effective therapy has been developed for the treatment of both 
choriocarcinoma and molar pregnancy, but the key to successful management of 
these patients lies in their prompt diagnosis and careful monitoring of response to 
treatment (Green-Thompson, 1986). Fortuitously, these tumours elaborate the human 
chorionic gonadotrophin hormone (hCG) and its free alpha (a) and beta (B) subunits 
and hence a ready marker for the tumour exists. 
Human chorionic gonadotrophin is one of a group of glycoprotein hormones, which 
includes luteinising hormone (LH), follicle stimulating hormone (FSH) and thyroid 
stimulating hormone (TSH). These hormones are composed of two dissimilar 
subunits designated a and B, which are bound non-covalently in the intact molecule. 
The B-subunit of each glycoprotein hormone is unique and is responsible for the 
respective biological and immunological properties of the glycoproteins. In contrast, 
all four hormones possess an identical a-subunit which is coded for by a single gene 
(Fiddes and Goodman, 1979). 
The measurement of hCG and its free B-subunit, as so-called BhCG, for the diagnosis 
and monitoring of therapy in patients with GTD is now routinely practised 
throughout the world (Vaitukaitis et al., 1972). However it has been demonstrated by 
Bagshawe (1975) that when serum BhCG can no longer be measured by current RIA 
methods, up to 10" tumour cells may remain undetected. In addition, there have been 
isolated reports of two patients with choriocarcinoma in whom BhCG was 
undetectable in the serum but who appeared to be secreting only the a-subunit 
(Dawood et al, 1977). Furthermore, it has been suggested that measurement of free 
a-subunit rather than intact hCG or the free B-subunit is a more effective means of 
detecting persistent trophoblastic disease as well as tumour recurrence following 
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treatment (Quigley et al, 1980a and b). 
Radioimmunoassays which measure the free a-subunit of hCG have been developed, 
but in general lack the specificity and sensitivity required (Gaspard et al, 1980; 
Kohorn et al, 1981). These assays employ polyclonal antisera which also detect 
epitopes common to the pituitary gonadotrophins. Thus there is a need to produce 
monoclonal antibodies which recognise regions of the free a-subunit which are 
hidden in the intact gonadotrophins. Such antibodies would provide the required 
specificity for use in RIAs but are limited in their use by their inherent lack of high 
affinity for the antigen. 
Fortunately, this drawback may be overcome by using monoclonal antibodies as 
labelled reagents in an alternative assay system, the immunoradiometric assay 
(IRMA), described by Miles and Hales (1968). The IRMA, particularly the two-site 
sandwich version of the assay, has been shown to provide greater sensitivity in 
addition to allowing enhanced specificity. This is a consequence of the use of two 
antibodies in excess to detect the analyte, each directed at a different epitope on the 
target molecule. The first antibody, referred to as the capture antibody, is usually 
linked to a solid-phase to facilitate easy separation and is added in excess relative to 
the target hormone to enhance antibody-antigen interaction, thereby allowing 
increased sensitivity in the measurement of analyte. The second antibody, referred 
to as the detection antibody, is labelled with a radioactive isotope or an enzyme to 
detect antigen already bound to the capture antibody. 
The application of monoclonal antibodies specific for the free a-subunit to a highly 
sensitive IRMA format is an obvious need. Hence this study was undertaken firstly, 
to raise and characterise monoclonal antibodies to the free a-subunit, secondly to 
develop an IRMA using these antibodies and finally to establish whether 
measurement of free a-subunit has any clinical advantage. 
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CHAPTER 1 
PRODUCTION OF MONOCLONAL ANTIBODIES TO THE ALPHA-
SUBUNIT OF HUMAN CHORIONIC GONADOTROPHIN 
The role of reason in research is not so much in exploring the frontiers of 
knowledge as in developing the findings of the explorers. 
Beveridge WIB [1908 - J 
1.1 INTRODUCTION 
Monoclonal antibodies derive their name from the fact that they are produced by a 
clone of cells which is descended from a single hybrid cell known as a hybridoma. All 
the cells in the clone produce antibody molecules of identical amino acid sequence 
which bind to a single epitope on the antigen. Thus monoclonal antibodies have an 
extremely high degree of specificity and their use in immunoassays, especially in two-
site immunometric assays, allows reliable quantitation of biological analytes (Miles 
and Hales, 1968). The purpose of this study was to raise monoclonal antibodies to 
the free a-subunit of human chorionic gonadotrophin (hCG) for use in a two-site 
immunoradiometric assay. 
The method chosen for the raising of monoclonal antibodies was essentially that 
described by Kohler and Milstein (1975). This method is based on the fusion of 
myeloma cells, which are capable of permanent growth in culture, with actively 
dividing splenic B lymphocytes triggered by antigenic stimulation of the donor animal. 
The success of this technique relies on the selection of only the hybrid cells. While 
spleen cells are unable to grow in culture, unfused myeloma cells soon overgrow the 
small percentage of newly generated hybridomas unless they can be selectively 
excluded. To this end, the myeloma cell is first made genetically defective in its 
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nucleotide salvage biosynthetic pathway by selecting for mutants that are resistant to 
either 8-azaguanine, 6-thioguanine or 5-bromo-2-deoxyuridine. Such cell lines are 
unable to grow in Littlefield's 'HAT' medium, containing hypoxanthine, aminopterin 
and thymidine (Littlefield, 1964). As aminopterin blocks de novo biosynthesis of 
purines and pyrimidines, a cell's survival in HAT is dependent upon its ability to 
utilise exogenous hypoxanthine and thymidine through these salvage biosynthetic 
pathways. Kohler and Milstein used a myeloma cell line selected for resistance to 8-
azaguanine which also has a deficiency in the enzyme hypoxanthine guanine 
phosphoribosyl transferase (HGPRT), making it unable to grow in HAT medium. 
Fusion of these cells with normal spleen cells which possess this enzyme, however, 
produces hybridomas resistant to HAT selection. 
The major steps involved in the raising of monoclonal antibodies to the free a-
subunit are the immunisation of a suitable spleen donor with the free a-subunit using 
an appropriate immunisation protocol; the maintenance in culture of a myeloma cell 
line deficient in an enzyme of the nucleotide salvage pathway; the fusion of 
immunised spleen cells with myeloma cells; the selection of hybridomas using HAT 
medium; the screening for the antibody in supernatant fluids; the maintenance of 
selected hybridomas; the production of ascitic fluid and finally the isolation of the 
antibody. These steps are described in detail in this chapter. 
1.2 IMMUNIZATION OF MICE 
When a foreign substance or antigen is injected into an animal, the appropriate B 
lymphocyte populations are stimulated to produce antibodies which recognise many 
different sites on the antigenic molecule. It is possible to generate antibodies against 
substances that are not normally antigenic, eg. hormones, by using an adjuvant which 
renders them antigenic (Freund, 1956). In addition, it is known that repeating 
injections of the same antigen in a highly aggregated form favours a strong antibody 
response (Goding, 1986). 
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1.2.1 Choice of Lymphocyte Donor 
The mouse is preferred as the lymphocyte donor because of the availability of 
suitable mouse myeloma cell lines. All currently available mouse myeloma cell lines 
used for hybridoma production are of Balb/c origin and this strain of mouse was 
therefore chosen for initial immunization in this study. Moreover, the choice of 
Balb/c mice for immunisation allows the resulting hybridomas to be grown as 
tumours in the same mouse strain. 
1.2.2 Materials and Methods 
"Tie immunization protocol used is based on that described by Siddle and Soos 
(1981). 
Ten Balb/c mice (obtained from the Medical Research Council, Research Institute 
for Diseases in a Tropical Environment, Durban) aged between 6 and 12 weeks 
were used. Primary immunization was carried out subcutaneousiy or intraperitoneally 
with free a-subunit of hCG (CR123 reference preparation; section 3.3) in doses 
ranging from 5 - 10 jug in Freund's complete adjuvant. After a rest period of 2 to 3 
months, a booster dose was given intraperitoneally in Freund's incomplete adjuvant. 
The production of antibodies against the free a-subunit was monitored by examining 
serum antibody titres in blood taken from the tail vein four days after the first 
booster dose was given. To obtain blood the mice were prewarmed to 40 ° Cand held 
in a fixed position in a cone. The tail vein was swabbed with alcohol and a nick 
made into the artery with a clean scalpel blade. Blood was collected in a microfuge 
tube and allowed to clot; after centifugation the supernatant serum was collected 
using a pasteur pipette. 
The serum was screened for antibodies to the free a-subunit in an enzyme-linked 
immunosorbent assay (ELISA) system described in section 1.7. 
Three to four weeks after sufficiently high titres were obtained a divided 
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intravenous/intraperitoneal dose ranging between 50 and 150 ng of free a-subunit 
(CR123 reference preparation) in saline was injected into a mouse showing a high 
titre of the desired antibody. This final boost was given to allow most of the 
circulating antibodies to be cleared from the blood stream of the mouse, resulting in 
a stronger immune response. 
1.2.3 Results and Comment 
In Table 1.1 the antibody titres obtained four days after the first booster dose was 
given, are represented. Good titres were achieved in all 10 mice immunised, 
indicating the use of an adequate antigen dose and a suitable immunisation protocol. 
Immunisation protocols for the generation of immune lymphocytes for hybrid 
formation are varied, but they are comparable in procedure. The timing between 
injections and the amount of antigen used must be determined for each antigen. A 
critical feature of all immunisation protocols is the timing of the final antigen boost 
relative to the time of cell fusion. This boost should be delivered 3 - 4 days prior to 
removal of the spleen for hybridisation with the myeloma cell line. In a series of 
early hybridisation experiments, Kohler found that the yield of specific, antibody-
producing hybridomas increased up to 3 days after the booster injection and 
subsequently decreased (Milstein, 1986). 
For many antigens, special measures must be taken to increase the yield of 
hybridomas secreting monoclonal antibody of the desired specificity and/or affinity. 
Stahli et al (1980), for example, found it necessary to hyperimmunise mice with the 
hormone hCG by repeated injections with the glycoprotein in Freund's complete 
adjuvant. Final immunisation was without adjuvant and required large amounts of 
antigen injected i.v. in 200 Mg aliquots on each of three successive days, beginning on 
day 4 prior to fusion. Similar immunisation regimens have succeeded in producing 
hybridomas to the human leucocyte interferons (Staehelin et al, 1981). In the 
current study final immunisation required a large divided intravenous/intraperitoneal 
dose of free a-subunit ranging between 50 - 150 Mg which was injected 3 - 4 days 
prior to fusion. 
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Table 1.1 Mean optical densities obtained after sera of immunised mice were tested 


























































Results represent means of duplicate samples of mice sera. 
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The purity of the antigen is another important factor in determining the final yield 
of antigen-specific hybridomas. Immunisation with crude preparations results in the 
stimulation of many B-cell clones producing antibodies to epitopes other than those 
of interest. Thus, a relatively pure free a-subunit preparation was used for 
immunisation to yield a higher percentage of hybridomas producing antibody of the 
desired specificity. 
1.3 MYELOMA CELL LINE 
A myeloma cell line which lacks HGPRT activity is required for fusion with 
immunised spleen cells to allow for the selection of hybridomas. In species which are 
dependent on exogenous purines or purine nucleosides for the formation of purine 
nucleotides, the salvage of preformed hypoxanthine or guanine can be initiated by 
HGPRT activity. Clearly, in a cell line which lacks HGPRT activity, the cells cannot 
grow or survive in a medium in which the sole source of exogenous purine is 
hypoxanthine and guanine; nor can HGPRT activity be blocked by 8-azaguanine, 
which is a guanine derivative and substrate analogue. 
These cells therefore only grow in media which are enriched with purine nucleotides. 
The enzyme deficiency can be exploited to favour cells which have fused with cells 
not lacking in the enzyme by the simple expedient of manipulating the composition 
of the growth medium. 
The cell line chosen for fusion should be of the same species as the immunised mice 
so that the resulting hybrids can be grown in the same strain for large scale antibody 
production. Furthermore, for a higher yield of spleen cell derived immunoglobulins, 
the myeloma cell line should preferably not secrete any immunoglobulin molecule. 
The most commonly used cell lines for hybridoma production are descendents of 
MOPC-21 which have been selected for HAT sensitivity and loss of endogenous 
immunoglobulin heavy chains (eg. P3-NSl-Ag 4-1; abbreviated NS) or loss of both 
heavy chains (eg. X63-Ag 8.653, abbreviated, NS-1). Of these, the NS-1 cell line is 
the most commonly used. 
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1.3.1 Choice of Myeloma Cell Line 
The NS-1 cell line was chosen for fusion with spleen cells in this study because it was 
readily available and most importantly, is of the same species as the immunised 
animal. In addition, NS-1 cells do not express the heavy chain of the immunoglobulin 
but only synthesise the k light chains which are degraded intracellularly and not 
secreted. Fusion of NS-1 cells with spleen cells results in the production of active 
antibody-secreting hybrids. The immunoglobulins secreted by the hybrid cell consist 
of only spleen cell heavy chains, but the k light chains are derived from both spleen 
and NS-1 cells. 
1.3.2 Method of Culture 
1.3.2.1 Preparation of Culture Medium 
Medium for the culture of NS-1 cells was made up of the following components: 
372 ml RPMI 1640 with NaHC03 (liquid) [Flow Laboratories, Scotland, 
UK] 
50 ml horse serum (heat inactivated) [M.A.Bioproducts, Walkersville, MD, 
USA] 
50 ml fetal calf serum (heat inactivated) [Flow] 
10 ml hepes buffer (1 mol/7) [Sigma Chemical Company, St Louis, USA] 
10 ml anti-PPLO Agent [Gibco, UK] 
5 ml L-glutamine (200 mmol//) [Flow] 
2 ml penicillin/streptomycin (5000 IU/ml / 5000 Mg/ml) [Flow] 
1 ml fungizone (250 Mg/ml) [Flow] 
1.3.2.2 Preparation of 8-Azaguanine Medium 
A vial of lyophilized concentrate of 8-azaguanine (Sigma) was reconstituted in 10 ml 
of sterile distilled water. One ml of this solution was dissolved in 50 ml of culture 
medium, prior to use. 
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1.3.2.3 Maintenance of Myeloma Cells 
NS-1 cells (gift from M.Conradie, Natal Institute of Immunology, Pinetown) were 
grown in RPMI 1640 culture medium at a concentration of 1 - 8 x 105 cells/ml." Every 
two months NS-1 cells were passaged through 8-azaguanine medium to ensure that 
a HGPRT deficient cell line was maintained. 
A week before fusion cells were stabilized at a logarithmic phase of growth (2 - 10 
x 105 cells/ml). To ensure this, cells were counted in a haemocytometer and the 
culture was appropriately diluted with fresh medium every second day. This growth 
phase is crucial because rapidly dividing cells are a requirement for successful 
hybridisation. Furthermore, the viability of cells during the exponential growth phase 
is generally greater than 95%. Cells were grown to a sufficient culture volume to 
yield 107 cells for each spleen used. 
On the day of fusion, cells were pooled in a 50 ml conical centrifuge tube (Nunc, 
Kamstrup-DK-4000, Ruskilde, Denmark), harvested by centrifugation at 400 g for 5 
min; cells were then washed 3 times with 10 ml serum-free culture medium and 
recovered by centrifugation each time. The final pellet was resuspended in 10 ml 
serum-free culture medium; the viability was determined by the trypan blue exclusion 
test and the concentration adjusted to 106 cells/ml. 
1.4 SPLEEN CELLS 
Only one percent of spleen cells actively secrete immunoglobulins while up to ten 
percent of hybrid cell lines secrete antibody (Goding, 1986). This may be explained 
by preferential fusion of myeloma cells with activated B cells. On the other hand it 
may be that myeloma cells have the ability to activate non-secreting B cells to rapid 
secretion (Eshhar et al., 1979). It is known that the spleen cells which fuse with 
myeloma cells are larger than average and have recently undergone antigenic 
stimulation and blast formation (Andersson and Melchers, 1978). This consideration 
stresses the need to ensure adequate antigenic stimulation shortly before fusion 
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attempts. 
1.4.1 Removal of Spleen 
On the day of fusion a mouse immunised 3 - 4 days previously was sacrificed by 
cervical dislocation. The animal was swabbed with 70% alcohol, the superficial skin 
pinched up over the left side of the abdomen and a small cut made over the spleen 
to expose the peritoneum. The spleen was removed under aseptic conditions and 
transferred to a petri-dish containing serum-free culture medium. 
1.4.2 Preparation of Spleen Cells 
A spleen cell suspension was prepared by teasing out the cells with a pair of bent 
sterile needles. Clumps were broken up to suspend cells. The debris was allowed to 
settle under gravity and the cell suspension was transferred to a sterile centrifuge 
tube and centrifuged at 400 g for 5 min; the supernatant was aspirated, the pellet 
resuspended in 5 ml 0.85% NH4C1 and left on ice for 10 min to allow red cell lysis. 
Spleen cells were washed 3 times with 10 ml serum-free culture medium and the cells 
recovered between each wash by centrifugation. The final pellet of spleen cells was 
resuspended in 10 ml serum-free culture medium. The number of viable cells per ml 
was determined by the trypan blue exclusion test and the cell number adjusted to 107 
cells/ml. 
1.5 FUSION PROTOCOL 
Successful hybridisation requires fusion of the membranes of both cells. The Sendai 
virus was used earlier as a fusing agent but most hybridomas are currently produced 
using polyethylene glycol (PEG) (Pontecorvo, 1976; Galfr'e et al, 1977). The 
mechanism of fusion is still poorly understood and it has been suggested that both 
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the PEG itself and an unidentified contaminant in the PEG are required for fusion 
(Wojciezsyn et al., 1983). 
Fusion results in the formation of multinucleated cells called heterokaryons (Ringertz 
and Savage, 1976). The nuclei of heterokaryons fuse at the subsequent cell division, 
and thereafter daughter cells possess an approximately equal share of genetic 
material. 
The fusion method chosen in this study is a modification of that described by Oi and 
Herzenberg (1980). 
1.5.1 Materials and Methods 
1.5.1.1 Preparation of PEG solution 
PEG 1500 (3.5 g, Sigma) was autoclaved (120°C,1.2 kg/cm2) and 500 /xl of dimethyl 
sulphoxide (DMSO) (Merck, Darmstadt, W.Germany) and 6.5 ml sterile serum-free 
culture medium were added whilst the PEG was still liquid. The pH of the solution 
was adjusted to 8.0; 1 ml portions of this solution were stored at 4°C. 
1.5.1.2 Fusion 
Spleen cells (1 x 108) and NS-1 cells (1 x 107) were pooled in a conical 50 ml plastic 
centrifuge tube. The cell suspension was centrifuged and washed once in 10 ml 
serum-free medium. The medium was aspirated after centrifugation and the cells 
resuspended in the remaining medium by gently tapping the side of the centrifuge 
tube. At room temperature, 1 ml of the PEG solution was added slowly, over 1 min 
with constant stirring. This was followed by a series of dilutions as follows: 
1 ml serum-free medium was added slowly whilst shaking for 1 min, 
2 ml serum-free medium was added slowly whilst shaking for 2 min, 
4 ml serum-free medium was added slowly whilst shaking for 2 min, 
8 ml serum-free medium was added slowly whilst shaking for 3 min. 
The cells were then pelleted gently (200 g for 10 min). 
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1.5.2 Comment 
Several technical factors were found to be of importance in increasing the yield of 
hybrids and the following points summarise the critical aspects of the various 
procedures. Of major importance for successful fusion was the use of actively dividing 
myeloma cells, maintained in mid-log growth for a week before fusion. The 
concentration of PEG used in the fusion was also important; it is known that 
concentrations less than 30% result in very few hybrids being formed while 
concentrations greater than 50% are toxic. A recommended concentration of PEG 
(35%) was chosen to ensure that a slight overexposure of PEG to cells did not result 
in damage to cells (Gefter et al, 1977). Dimethyl sulphoxide was added to the PEG 
to increase the pliability of the cell wall, allowing cells to fuse easily (Norwood et al, 
1976). The pH of the solution was adjusted to 8.0 to increase hybrid frequency as 
shown by Sharon et al (1980). 
1.6 SELECTION OF HYBRIDOMAS 
The fusion procedure results in the formation of various cell combinations. In 
addition to myeloma-spleen cell fusions, spleen-spleen and myeloma-myeloma fusions 
also occur. Thus, a selection procedure is necessary to produce a long-term hybrid 
cell line. The most commonly used selection procedure is that described by Littlefield 
(1964). 
1.6.1 Principle 
This procedure depends on the fact that when the main synthetic pathway for purines 
and pyrimidines is blocked by the folic acid antagonist, aminopterin, there is an 
alternative 'salvage' pathway by which the cells are able to synthesise these 
nucleotides utilising an exogenous source of hypoxanthine and thymidine (Fig. 1.1). 
Unfused myeloma cells and cells arising from myeloma-myeloma fusions, lack the 
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Figure 1.1 Metabolic pathways relevant to hybrid selection in medium containing 
hypoxanthine, aminopterin and thymidine (HAT). When the main 
synthetic pathways are blocked with the folic acid analogue 
aminopterin (*), the cell must depend on the 'salvage' enzymes 
HGPRT and thymidine kinase, (after Goding, 1986) 
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enzyme HGPRT and are therefore incapable of growing in HAT medium, because 
both the main and salvage pathways are blocked. There is no positive selection 
against the growth of spleen cells and spleen-spleen cell fusions in this scheme. 
Passive selection takes place because normal spleen cells have a limited growth 
potential in culture. However, a HGPRT negative myeloma cell can be made to grow 
in HAT medium if it is provided with the missing enzyme by fusion with an HGPRT 
positive spleen cell. 
1.6.2 Materials and Methods 
1.6.2.1 Preparation of HAT and HT medium 
A vial of lyophilised HAT or HT (Sigma) was reconstituted in 10 ml of sterile 
distilled water. Aliquots of this stock solution were stored at 4°C. One ml of this 
solution was added to 50 ml of culture medium, prior to use. 
1.6.2.2 Selection of Hybrids 
After fusion, the hybridised cells were resuspended in 50 ml of HAT selective 
medium which contained 5% human umbilical cord serum (HUCS). It has been 
shown that HUCS is a potent growth promoter of hybridoma cells at low plating 
densities (Westerwoudt et al., 1983). The cell suspension was distributed into 5 x 96-
well plates in 100 jtil portions. Plates were incubated at 37 ° C in an adequately 
humidified and aerated (5% C02-in-air) incubator (Flow) for 7 days. 
After this period, a further 100 jul of HAT medium containing HUCS was added to 
each well. When the medium became acidic (approximately 14 days after fusion) as 
indicated by a change in the colour and when the growth of hybridomas was seen 
under the microscope, 100 M1 supernatant was removed for screening from each well 
showing growth (see section 1.7). The wells were replenished with HT medium. 
Selection in HAT was terminated after two weeks when it was assumed that all the 
parental myeloma cells were dead and that any growing cells were myeloma-spleen 
hybrids. 
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Once the results of the screening became available, clones secreting the desired 
antibody were transferred in HT medium to 24-well plates. The clones were grown 
in HT medium to dilute out the aminopterin and to allow the hybrids to regain their 
enzyme activity. The selected clones were then cultured in large numbers for freezing 
and cloning. These procedures took place once a healthy, debris-free hybridoma 
culture was obtained. 
1.6.3 Results and Comment 
Between 10 and 60% of all wells plated had growth of hybrids. This range represents 
the results of seven fusions. 
The initial cloning efficiency was low (10%) but improved after each performance 
possibly due to a more careful control of the NS-1 crucial exponential growth phase. 
It was also necessary to perform several fusions before hybridomas secreting the 
desired antibodies were obtained. 
Only the screening results of the successful fusion are discussed. Two supernatants, 
71C3 and 75C8, were positive for a-subunit antibody in the ELISA, with optical 
density (OD) readings of 1.55 and 1.90, respectively. These positive clones were 
screened on several occasions to ensure that they were not lost by overgrowth of a 
negative clone in the same well. In addition, all negative clones were tested two to 
three times to make sure that positive clones in low concentration were not missed. 
1.7 SCREENING PROCEDURE 
The choice of an appropriate screening assay is of major importance to hybridoma 
production. In principle, any method capable of detecting an antibody of the desired 
specificity may be used but a method that is accurate, reproducible and rapid is 
desirable; quick decisions about which culture wells to save or discard are essential 
to contain the volume of cultures. Quantitative results are mostly unnecessary in 
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hybridoma screening since the cells can be cloned if volume is required. The most 
appropriate assay for the screening of these hybridomas is an enzyme-linked 
immunosorbent assay (ELISA). 
1.7.1 Principle 
ELISAs utilize an antigen bound to a solid phase which in turn binds to a specific 
antibody. A second antibody conjugated to an enzyme such as horseradish peroxidase 
(HRPO) then binds to the antigen. After washing away unbound material, the bound 
enzyme is revealed by the addition of a substrate which undergoes a colour change 
proportional to the amount of enzyme present. 
1.7.2 Materials and Methods 
1.7.2.1 Preparation of Buffers 
Carbonate buffer - 0.015 mol/l Na2C03, 0.036 mol/l NaHC03, 0.02% NaN3; pH 9.6 
Phosphate buffered saline (PBS) with BSA - 0.15 mol/l NaCl, 0.04 mol/l Na2HP04, 
0.01 mol/l NaH2P04.H20, 0.4% BSA, 0.02% NaN3; pH 7.4 
Tris-saline-Tween (TST) buffer - 0.05 mol/t Tris, 0.1 mol/l NaCl, 0.05% Tween-20; 
pH8.0 
1.7.2.2 Screening Procedure of Supernatant Fluid 
1.7.2.2.1 Coating of Microwell Plates 
Free a-subunit antigen (100 jul at a concentration of 5 Mg/ml; CR123 reference 
preparation) in carbonate buffer was dispensed into each well of a 96-well ELISA 
plate (Nunc, high binding capacity) and incubated in a humidified box overnight at 
room temperature. The unbound antigen solution was aspirated the following day and 
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the wells were washed once with PBS containing 0.4% BSA. To block any unbound 
sites, wells were incubated at 37°Cfor 2 - 3 hours with 250 /xl of PBS containing 
0.4% BSA. Wells were then washed once with TST buffer and finally with distilled 
water. After washing, plates were dried by tapping on absorbent paper and stored at 
4°Cin a dry atmosphere. 
1.7.2.2.2 Screening for Antibody in Supernatant Fluid 
Supernatant fluid was screened for antibodies by adding 50 /J.\ from each culture well 
to an ELISA plate well. Culture medium was used as negative control; as positive 
control a 1/100 dilution of ascitic fluid (designated 34E2) from Balb/c mice with 
peritoneal implants of free a-subunit producing hybridomas (Norman et al., 1985) 
was used. ELISA plates were incubated at 45°Cfor 30 min in a humidified box. 
After incubation, wells were washed 3 times with TST buffer. 
Fifty microlitres of conjugate (sheep anti-mouse IgG HRPO, courtesy Dr. J. 
Conradie, Natal Institute of Immunology, Pinetown) at an appropriate dilution (see 
section 1.7.3) were dispensed into each well and incubated at 45 ° Cfor 30 min in a 
humidified box. The wells were then washed 3 times with TST buffer to remove 
excess second antibody. 
1.2 phenylenediamine dihydrochloride (7.2 mg) [OPD-2HC1] was dissolved in 6 ml 
substrate solution (Natal Blood Transfusion Services, Pinetown) a short while before 
use and 50 IJLI were dispensed into each well. Plates were left covered for about 20 
min for colour development. One hundred microlitres of 1.5 N HC1 (Merck) were 
then added to each well to stop the reaction and the absorbance was read at 498 nm 
on an ELISA plate reader (Biodata Instruments Inc., USA). 
1.7.2.3 Optimization of ELISA 
The following steps were undertaken to optimise assay conditions: 
i) ELISA plates (Nunc) were coated with 100 jul free a-subunit (CR123 reference 
preparation) ranging from 1 - 10 /xg/ml. 
ii) Fifty microlitres of conjugate (sheep anti-mouse IgG HRPO) at dilutions 
ranging from 1/50 - 1/150 or PBS as blank were added. 
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iii) Wells were washed, between incubation steps, either once, twice or three times 
using an Eppendorf multipipette. 
1.7.3 Results and Comment 
Table 1.2 shows that at a conjugation dilution of 1/50 little difference in the OD 
readings of the positive control sample in wells coated with varying concentrations 
of antigen was seen. The concentration of coating antigen chosen for use in the 
ELISA was 5 Mg/ml. The optimal conjugate dilution, however, was found to vary 
(results not shown) from batch to batch of conjugate preparation necessitating 
assessment of each batch before use. 
The number of times the wells were washed made a considerable difference to the 
background reading especially when a low conjugate dilution was used. Three washes 
after each incubation step were optimal in reducing the background reading. 
The coefficients of variation between inter- and intra-assay of samples were found to 
be < 10% at the optimal conditions described above. 
In practice, the assay was found to be simple, rapid, specific and reproducible, 
allowing for large numbers of supernatants to be screened accurately. 
1.8 MAINTENANCE OF HYBRIDOMAS 
After identifying the cultures with positive antibody production, the cells were 
transferred to wells in 24-well culture plates; 1 ml medium was added to each well 
prior to incubation. This was the first step in expanding the cell lines for cloning and 
freezing. Cells were frozen and stored in liquid nitrogen as soon as a sufficient 
number of cells was obtained as an insurance against contamination and genetic drift. 
When required, cells were thawed. 
17 
Table 1.2 Mean optical densities obtained after the positive control sample was 














































































Results represent means of duplicate samples. 
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Hybridomas secreting the desired antibody were cloned to reduce the risk of 
overgrowth by non-producer cells and to ensure homogeneity and monospecificity of 
the antibody. Cloning by limiting dilution is the most commonly used procedure. 
1.8.1 Principle of Cloning Procedure 
If cells are grown in small numbers, the fraction of wells with growth should follow 
the Poisson distribution, f (0) = e' (Lefkovits and Waldermann, 1979) where f (0) 
is the fraction of wells with no growth and lambda is the average number of clones 
per well. If lambda = 1 , then f (0) = e'1 = 0.37 (natural antilog). 
In other words, to obtain a reasonable probability that wells with growth contain 
single clones, at least 37% of wells should have no growth (this analysis assumes a 
cloning efficiency of 100% and that there is no clumping of cells). 
1.8.2 Materials and Methods 
1.8.2.1 Freezing 
Cells were prepared for freezing during the log phase of growth. They were pooled, 
centrifuged (400 g for 5 min) and then resuspended in the appropriate culture 
medium at a concentration of approximately 2 x 106 cells/ml. The cell suspension was 
placed on ice to cool and after cooling an equal volume of cold culture medium 
containing 20% DMSO (a cryoprotectant) was added dropwise to the cold cell 
suspension whilst swirling. One millilitre portions of the final cell suspension were 
dispensed into cryotubes and then placed in a polystyrene box, covered with dry ice 
and left for 24 hours. The following day the cryotubes were transferred to a liquid 
nitrogen cryostat (Union Carbide, USA). 
1.8.2.2 Thawing 
Vials were removed from liquid nitrogen and thawed quickly at 37 °C until only a 
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little ice remained. The thawed cells were added to 9 ml of appropriate culture 
medium and centrifuged (400 g for 5 min). The supernatant was aspirated and the 
cells resuspended in culture medium to give a cell concentration of 1 - 2 x 105 
cells/ml. The cells were then incubated at 37°Cand the medium changed after 24 
hours to ensure that all the DMSO was removed. 
1.8.2.3 Cloning 
Cells were resuspended, counted and an appropriate plating concentration selected 
(duplicate plates of each culture at 40 cells/ml and 10 cells/ml were used). Each cell 
suspension was initially diluted (1/100) in HT medium and further diluted in HT 
medium supplemented with HUCS. Portions (100 jul) of each cell suspension were 
distributed into a 96-well plate. When growth was observed in the wells 
(approximately 7 days after plating), each well was replenished with 100 is\ of 
medium. A sample of supernatant was removed for screening once good growth was 
visible (approximately 14 days after plating) and wells were replenished with fresh 
medium. Plates with a percentage growth of less than 60% were used to ensure 
monoclonality (see section 1.8.1). Clones were then selected (based on clone size and 
appearance) and transferred to a larger dish for re-cloning and freezing. This 
procedure was repeated until stable clones were established. 
1.8.2.4 Large Scale Cultures 
Once the monoclone was established, it was grown in HT medium for a further 2 -
3 passages. The cells were then gradually transferred to progressively larger cultures 
vessels (6-well plates, followed by 5 ml petri-dishes), taking care to maintain 
exponential growth. When large cell numbers were achieved, some cells of each clone 
were frozen. The remaining cells were grown in medium containing half the 
concentration of HT, then quarter the concentration and finally in normal culture 
medium; culture supernatants were removed and screened for antibody activity at 
frequent intervals. 
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1.8.3 Results and Comment 
Hybridomas 71C3 (71) and 75C8 (75) often grew slowly and were intolerant of low 
cell densities. The volume of each cell culture was therefore expanded gradually, at 
a rate that was determined empirically. In addition, each hybrid cell line showed a 
different growth rate. When sufficient cell numbers were obtained cell stocks were 
frozen in liquid nitrogen and at the same time, some cells were subjected to a cloning 
procedure. 
After the first cloning, two clones (baby clones) were selected from each parent cell 
line, viz., 71C3C7, 71C3E3, 75C8C4 and 75C8E5. Each baby clone was grown in large 
numbers and stocks of each were frozen away before recloning. After recloning each 
clone selected (71C3C7G9, 71C3C7H2, 71C3E3C7, 75C8C4C2, 75C8C4G9, 
75C8E5G3) was assumed to be homogeneous and referred to as a monoclone. Each 
monoclone was grown to large numbers and stocks of each were frozen in liquid 
nitrogen. Of these monoclones, two (71C3C7G9 and 75C8E5G3) were chosen for 
peritoneal implants in mice. 
Further recloning of the established antibody-producing cell lines became necessary 
when these cells had been grown for long periods. Somatic mutation or chromosome 
loss may have occurred because it was observed that some cells of each line lost the 
ability to produce antibody. 
The Poisson distribution shows that if cells are plated at a concentration of 5 cells/ml 
and growth is observed, the clone must have originated from a single cell (Lefkovits 
and Waldermann, 1979). Since the cloning efficiency and visibility is seldom 100%, 
cells were plated at a higher concentration. Cloning efficiency was improved by the 
presence of 5% HUCS in the culture medium. Recloning was carried out to allow 
cultures to eliminate any variant cells, especially spontaneous non-secreting variants. 
To ensure that the hybridomas were stable and single-cell cloned, the cloning 
procedure was repeated until every well tested was positive. 
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1.9 PRODUCTION OF ASCITIC FLUID 
Large amounts of antibody can be obtained when cells are grown as tumours in 
appropriate histocompatible mice. The serum or ascitic fluid can contain 
approximately 1000 times the antibody concentration found in culture (Goding, 1986). 
In most instances, intraperitoneal injection (i.p.) of 106 - 107 hybridoma cells into 
histocompatible mice will result in tumour formation after 2 weeks. The injection of 
the peritoneal irritant pristane (2, 6, 10, 14-tetramethylpentadecane) (Sigma) a few 
days prior to injection of the cells, increases the success rate of tumour development 
and the probability of ascitic fluid formation (Goding, 1986). 
1.9.1 Materials and Methods 
1.9.1.1 Preparation of Hybridoma Cells 
The cells chosen for ascites production were pooled and centrifuged (400 g for 5 
min). The supernatant was removed and the cells washed once in saline. The cells 
were then resuspended in a known volume of saline and the cell number adjusted to 
2 - 20 x 106 cells/ml. 
1.9.1.2 Peritoneal Implantation of the Hybridomas 
Mice were primed with 0.5 ml pristane i.p. 3 - 10 days prior to injection of cells. 
Between 1 - 10 x 106 cells suspended in 0.5 ml saline were injected i.p. into each 
mouse. After 14 - 28 days, ascitic fluid was tapped and collected in a clean tube. Cell 
debris was pelleted by centrifugation and the ascitic fluid collected and stored at 
-20 °C. 
1.9.2 Results 
An average of between 2 ml and 5 ml ascitic fluid was collected (14 days after 
inoculation) over a period of one week from each mouse injected with monoclone 
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71C3C7G9 (71) and 75C8E5G3 (75), respectively. 
1.10 ISOLATION OF ANTIBODY 
Although ascitic fluid contains a high titre of monoclonal antibody, it also contains 
a variety of proteins, some of which may be immunoglobulin molecules of unknown 
specificity. Isolation of the desired immunoglobulin is therefore essential. 
Knowledge of the antibody class is useful in determining the method of purification. 
1.10.1 Choice of Purification Method 
Affinity chromatography on Protein A-Sepharose was the method chosen for the 
purification of ascitic fluid because it was both readily available and suitable. 
1.10.2 Principle 
Staphylococcal protein A is a major cell component of most strains of Staphylococcus 
aureus. This protein has the property of binding the Fc-region of IgG with high 
affinity and specificity (Goding, 1978). Protein A, covalently attached to Sepharose 
beads serves therefore as a useful matrix for the binding of immunoglobulins. After 
attachment of the IgG to Protein A, the immunoglobulin is eluted under mild acid 
conditions. 
1.10.3 Materials and Methods 
1.10.3.1 Immunoglobulin Subtyping 
Immunoglobulins were subtyped by using an anti-mouse monoclonal isotyping kit 
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(Serotec, Oxford, England) which distinguishes between the IgG, IgM and IgA classes 
and the different subclasses of IgG, namely IgGl, IgG2a, IgG2b and IgG3. 
1.10.3.2 Protein Determinations 
The protein concentrations in ascitic fluid were determined by the method of Lowry 
et al. (1951). The electrophoretic composition of the preparations was determined 
using a Paragon Serum Protein Electrophoresis (SPE) Kit (Beckman). The protein 
pattern was visually interpreted by densitometry. 
1.10.3.3 Purification of Ascitic Fluid 
The electrophoretic pattern of the ascitic fluid before purification was first 
determined. Thereafter the immunoglobulins were precipitated by saturating the fluid 
with ammonium sulphate (about 400 g/l). The precipitate was collected by 
centrifugation, washed once with 10 ml 40% ammonium sulphate solution and then 
dissolved in Tris-HCl buffer (1 mol/7, pH 9.0). To remove the ammonium sulphate 
the solution was dialysed against PBS (0.15 mol/7, pH 7.2), using Spectrapor 
membrane tubing (Spectrum Medical Industries Inc., LA, USA) with a molecular 
weight cut off of 12000 to 14000 daltons. 
Immunoglobulin G was recovered from the crude preparation by affinity 
chromatography on Protein A-Sepharose (Pharmacia Laboratories, Uppsala, Sweden) 
as described below. A glass column (25 x 1 cm) was packed with Protein A-
Sepharose gel and washed thoroughly with 50 ml 0.1 mol// phosphate buffer, pH 8.0. 
A sample of the crude preparation containing approximately 15 mg of protein was 
applied to the column and left for a few hours to allow binding of IgG to Protein A. 
The column was then washed with 30 ml phosphate buffer, pH 8.0 and fractions were 
collected. Fractions containing high concentrations of protein were pooled (eluate 1). 
The eluting buffer (30 ml, 0.1 mol// citrate buffer, pH 5.5) was then applied and 
fractions were collected. Fractions containing high concentrations of protein were 
pooled (eluate 2). Glycine-HCl (20 ml, 0.2 mol//, pH 4.0) was then added to the 
column to elute any immunoglobulins that were still bound and fractions were 
collected. Each of these fractions was immediately neutralized with 1 mol// Tris-
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HC1, pH 9.0. 
Each pooled fraction was thoroughly dialysed as described previously and the 
electrophoretic protein pattern of each eluate was determined. 
1.10.4 Results and Comment 
Both monoclonal antibodies 71 and 75 were found to be of the IgGl subtype. 
Only the purification results of ascitic fluid 75 are presented; purification results of 
71 were very similar. The electrophoretic separation of ascitic fluid 75, before 
purification revealed the presence of a single gammaglobulin peak and various other 
proteins (Fig. 1.2). 
After purification by Protein A affinity chromatography, elution with phosphate 
buffer yielded some albumin and globulins but no gammaglobulin (Fig. 1.3). The 
pooled citrate buffer eluate however contained essentially gammaglobulin (Fig. 1.4). 
Although there have been reports on the inefficiency of Protein A affinity 
chromatography in the purification of mouse IgGl monoclonal antibodies (Goding, 
1980), good results were obtained when the above protocol was followed. The use of 
Protein A-Sepharose in the purification of IgGl subclass is also favourably reported 
by Ey et al. (1978). The results in this study are clearly not in doubt and hence this 
technique was adopted for isolation. 
1.11 SUMMARY 
Using the mouse hybridoma technique two clones secreting monoclonal antibodies 
to the free a-subunit of hCG were successfully cultured. These hybridoma clones 
were identified after screening all culture supernatants in an optimised a-subunit 
ELISA. Each hybrid was single-cell cloned several times until homogeneous stable 
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Figure 1.2 Electrophoretic pattern of ascitic fluid before purification, showing 
albumin, ata2, B and gammaglobulins. 
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Figure 1.3 Electrophoretic protein pattern of eluate 1 obtained after washing with 
0.1 mol// phosphate buffer, pH 8.0. 
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Figure 1.4 Electrophoretic protein pattern of eluate2 after elution with 0.1 
mol// citrate buffer, pH 5.5, showing a purified preparation of 
gammaglobulin. 
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cell lines were established. The monoclones were expanded and used for large-scale 
production of antibody in ascitic fluid. On subtyping, both antibodies were found to 
be of the IgGl subclass. Immunoglobulin G was recovered from ascitic fluid by 
affinity chromatography on Protein-A Sepharose. 
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CHAPTER 2 
CHARACTERISATION OF THE MONOCLONAL ANTIBODIES 
TO THE FREE ALPHA-SUBUNIT OF HCG 
The man of science has learned to believe in justification, not by faith, but 
by verification. 
Thomas Huxley [1825 - 1895] 
2.1 PURPOSE OF THE STUDY 
Monoclonal antibodies to the free a-subunit of hCG were raised and purified as 
described in the preceding chapter. The next step was to assess the quality of these 
antibodies to determine whether they meet the requirements of a specific and 
sensitive assay system. 
The purpose of this study therefore was to examine the two monoclonal antibodies 
(71 and 75) that were reactive with the free a-subunit of hCG and characterise 
them with respect to their specificity, affinity, ability to recognise distinct epitopes 
on the free a-subunit molecule and display cooperativity in binding. The 
characterisation of another monoclonal antibody, designated antibody 42 (described 
by Norman et al., 1985) which is also reactive to the free a-subunit of hCG, is 
included in this study for purposes of comparison. 
2.2 SPECIFICITY OF THE MONOCLONAL ANTIBODIES 
The specificity of the monoclonal antibodies for the free a-subunit was determined 
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by assessing cross-reaction with intact hCG and related glycoprotein hormones. Since 
an epitope present on the free a-subunit may also be exposed on the intact 
molecule, the specificity of the monoclonal antibody is defined by its ability to 
recognise an epitope on the a-subunit that is hidden in the intact dimeric form. 
2.2.1 Choice of Method 
The cross-reaction of the three monoclonal antibodies with the related glycoprotein 
hormones was assessed by a method which uses limiting concentrations of antibody. 
2.2.2 Materials and Methods 
Cross-reaction was expressed in percentage form as the ratio of intact glycoprotein 
hormone to free a-subunit which caused 50% inhibition of binding of a given 
quantity of radiolabeled free a-subunit to antibody when the antibody concentration 
was the limiting factor. 
The dilution of antibody which bound 50% of the measured amount of labelled free 
a-subunit was determined as a first step. This was done by diluting the antibody 
preparation serially (dilutions ranged from 1/20 to 1/5120 depending on the 
antibody) in phosphate buffer (0.067 mol//, pH 7.4). To 100 /xl of each dilution, 100 
/il (approximately 4 x 104 cpm) [12TJ-free a-subunit (iodination procedure described 
in section 3.4) were added. The tube contents were thoroughly mixed and left 
overnight at 4 ° C.The following day, labelled free a-subunit bound to antibody was 
precipitated by the addition of 200 jul 1% gammaglobulin (Sigma) and 1.0 ml 20% 
PEG (Merck). After vortex mixing, the precipitate was collected by centrifugation 
(1000 g x 10 min), the supernatant discarded and the tubes drained. The bound 
radioactivity in the precipitate was measured in a Berthold multihead gamma 
spectrometer. The percentage radioactivity bound was plotted against the antibody 
dilution and the dilution of antibody which bound 50% of the radiolabeled free a-
subunit was read off the graph. This limiting antibody dilution was then used in the 
measurement of cross-reactions with the related glycoprotein hormones. 
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Antibody (100 jul) at the appropriate dilution and 100 jtxl [12SI]-free a-subunit 
(approximately 4 x 104 cpm) were incubated with 100 /il volumes of increasing 
concentrations (ranging from 0.05 to 100 ng/ml) of unlabelled free a-subunit of 
hCG (CR123 preparation; section 3.3), hCG, LH, FSH and TSH (2nd IRP, a gift 
of National Pituitary Programme, National Institute of Health, USA) standards in 
phosphate buffer (0.067 mol/7, pH 7.4) at 37 ° Cfor 4 hours. The bound complex was 
precipitated by the addition of 200 fi\ 1% gammaglobulin and 1.0 ml 20% PEG and 
mixed well before centrifugation (1000 g for 10 min). The supernatant was decanted 
and the bound radioactivity in the pellet counted in a Berthold gamma 
spectrometer. 
The ratio (mass/mass) of glycoprotein hormone to free a-subunit expressed as a 
percentage which yielded a 50% inhibition of binding of the labelled free a-subunit 
to antibody was then calculated. 
2.2.3 Results and Comment 
The antibody dilution curves for antibodies 71 and 75 are shown in Figs. 2.1 and 2.2, 
respectively. The dilutions of antibodies 71 and 75 which bound 50% of labelled a-
subunit were read as about 1/130 and 1/1000, respectively, and these dilutions were 
used in the cross-reactivity studies. 
Crossreactivities with the glycoprotein hormones as calculated for the three 
antibodies are presented in Table 2.1; results are expressed as a percentage 
mass/mass ratio. 
Both antibodies 75 and 71 showed little cross-reaction to the intact glycoprotein 
hormones and are therefore more likely to recognise epitopes on the free a-subunit 
which are hidden by the folding of the 3-subunit in the intact molecule. Antibody 
71 showed a high cross-reaction with FSH initially, but after purification of the FSH 
preparation on Sephadex G100 (described in detail in section 3.6), the cross-
reactivity decreased by 40 - 50%. 
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1/20 1/40 1/80 1/160 1/320 
Antibody 71 dilution 
Figure 2.1 Antibody dilution curve of antibody 71 showing the dilution which 
bound 50% of the free a-subunit. 
1/20 1/40 1/80 1/320 1/640 1/1280 1/12560 1/5120 1/160 
Antibody 75 Dilution 
Figure 2.2 Antibody dilution curve of antibody 75 showing the dilution which 
bound 50% of the free a-subunit. 
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Table 2.1 Percentage cross-reactivity of the anti-a antibodies with the intact 
glycoprotein hormones. 
a-subunit hCG FSH LH TSH 
antibody 75 100% 3% 5% 8% 15% 
antibody 71 100% 5% 25% 14% 4% 
antibody 42 100% 330% 300% 100% 300% 
Cross-reactivity of the intact glycoprotein hormones is expressed as a percentage 
relative to binding of the free a-subunit (arbitrarily represented as 100%). 
35 
Antibody 42 on the other hand showed more binding to the intact glycoprotein 
hormones than to the free a-subunit. It would appear that this antibody recognises 
an epitope that is preferentially exposed when the a-subunit is combined with the 
5-subunit. This non-specificity for the free a-subunit renders it of little use in an a-
subunit immunoassay. 
2.3 BINDING AFFINITIES OF THE MONOCLONAL ANTIBODIES 
The strength or affinity of binding of an antibody to an antigen can be assessed in 
several ways. The method used in this study was that of Scatchard (1949). 
2.3.1 Principle 
Using Scatchard analysis the affinity of an antibody for its antigen is determined by 
plotting the ratio of bound to free antigen against the concentration of bound 
antigen. A straight line indicates that only one binding site or epitope is recognised 
while the slope reflects the affinity of binding; the ratio of the y and x intercepts 
(y/x) estimates the association constant, K,, and the reciprocal x/y the dissociation 
constant, K^ The relationship between the dissociation constant, or alternatively the 
association constant, and the affinity of the binding may be explained as follows: 
In terms of the law of mass action, the rate of a reaction in dilute solutions is 
proportional to the concentration of the reactants and is represented by the 
equation: 
[antigen] + [antibody] [antigen-antibody complex] 
where kt and k.j represent the association and dissociation rate constants, 
respectively. 
The forward reaction is a second order reaction in which the rate constant lq is 
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proportional to the product of the concentrations of the reactants and has the 
dimensions 1 , usually /mol'V. The reverse reaction is a first order 
cone x time 
reaction in which the rate constant k.{ is proportional to the concentration of only 
one reactant and has the dimensions of the reciprocal of time, usually s'1. 
At equilibrium the rate of the forward reaction is equal to the rate of the reverse 
reaction, that is, 
MAg][Ab] = MAbAg] 
The equilibrium constant of dissociation can therefore be determined from the 
above equation: 
[Ab] [Ag] = k, —si 
[AbAg] k, /mol's1 
= K, mol// 
Since K̂  is the reciprocal of K,, it follows that the smaller the value of the K̂  the 
greater will be the K, or binding affinity. 
2.3.2 Materials and Method 
The concentration of each antibody used was that which bound 50% of the 
radiolabeled free a-subunit (section 2.2.2). Portions (100 /xl) of antibody were 
incubated with 100 /xl [125I]-free a-subunit (about 0.38 ng, 40 000 cpm) and 100 /xl 
amounts of increasing concentrations of unlabelled free a-subunit, ranging from 0 
to 2000 ng/ml. The non-specific binding (NSB) was estimated by incubating 200 /LII 
phosphate buffer (0.067 mol//, pH 7.4) and 100 nl [,25I]-free a-subunit. The 
incubation procedure and precipitation of bound radioactivity using gammaglobulin 
and PEG were as described in section 2.2.2. The concentration of bound labelled 
free a-subunit (B) was determined by multiplying the proportion of labelled a-
subunit bound by the concentration (mol//) of the total a-subunit (labelled and 
unlabelled) available for binding. The unbound labelled free a-subunit (F) was 
calculated by subtracting the amount bound in cpm (specific and non-specific) from 
the total counts (T). The ratio of B/F was plotted against concentration of B for 
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each antibody using linear regression analysis. 
2.3.3 Results and Comment 
Scatchard plots of both antibodies 71 and 75 were straight lines indicating the 
presence of a single class of binding site or epitope. The dissociation constants of 
these two antibodies were 0.92 x 10'8 and 4.08 x 10'8 mol/l, respectively. The binding 
data for antibodies 71 and 75 are shown in Figs. 2.3 and 2.4, respectively. The 
dissociation constant of antibody 42, calculated by Norman et al. (1985) was 1.0 x 
10"7 mol//. 
All three antibodies showed relatively low affinities for the a-subunit which is not 
unexpected for monoclonal antibodies (Soos and Siddle, 1982). The binding affinities 
of antibodies 71 and 75, obtained in this study, differ from the data published by 
Norman et al. (1987) due to an error in the calculation of the dissociation constants 
in the previous study. In the current study antibody 71 showed an approximately 4 
and 10 fold higher affinity for the free a-subunit than antibodies 75 and 42, 
respectively. 
The comparatively low affinities of the monoclonal antibodies do not limit their 
value in immunoassays. Antibody affinity is not critical for the sensitivity of an 
immunoradiometric assay as the antibody is added in excess to maximise reaction 
with antigen (Miles and Hales, 1968). In this context therefore, the monoclonal 
antibodies 71 and 75, if produced in large quantities could be of great value. 
2.4 EPITOPE ANALYSIS 
A detailed analysis of the antigen binding sites for the different antibodies was 








0.1 0.2 0.3 0.4 
[125l] free a - subunit bound (10"8mol/l) 
Figure 2.3 Scatchard plot of antibody 71. The concentration of antibody 71 
which bound 50% of [125I] a-subunit was incubated with labelled a-
subunit and increasing concentrations of unlabelled a-subunit. 
Bound label (B) was measured and the unbound or free [125I] a-
subunit (F) was calculated by subtracting B from the total counts 
















kd = 4.08 X 10-8mol/l 
r= -0.8768 (n = 7) 
1.0 2.0 3.0 4.0 5.0 
[125l] free ce- subunit bound (10"8mol/l) 
Figure 2.4 Scatchard plot of antibody 75. The concentration of monoclonal 
antibody 75 which bound 50% of [125I] free a-subunit was incubated 
with labelled a-subunit and increasing concentrations of unlabelled 
a-subunit. Bound label (B) was measured and the unbound or free 
[125I] a-subunit (F) was calculated by subtracting B from the total 
counts (T). The dissociation constant (K )̂ was determined by 
calculating x/y intercepts. 
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2.4.1 Principle 
The ability of pairs of antibodies to bind simultaneously to an antigen is assessed 
when one antibody, immobilised on a solid phase (ELISA plate or cellulose) binds 
the antigen and having done so, exposes an epitope on the antigen which binds to 
another radiolabeled antibody. The amount of label bound is a measure of two-
site binding and hence antibody recognition of two distinctly different antigenic 
determinants. 
2.4.2 Materials and Methods 
All possible combinations of labelled and solid phase antibodies were assessed for 
two-site binding by the following two methods. 
2.4.2.1 ELISA Plate as Solid Phase 
One antibody was coated on to microtitre wells as described in the ELISA method 
(section 1.7); the final amount of antibody bound, determined empirically, was 5 
Atg/well. The other antibody was labelled with 125I (Amersham) using the 
Chloramine-T method as described in section 3.4. 
One hundred microlitres of free a-subunit (0.5 mg/7 in 0.067 mol// phosphate buffer, 
pH 7.4) or phosphate buffer as NSB were added to the wells and incubated at 37 ° C 
for 7 hours. The wells were then washed 3 times with Tris-saline-Tween (TST) 
buffer, pH 8.0 (section 1.7). Labelled antibody (about 100 000 cpm) was added to 
each well and the plates incubated overnight at 4 ° C.The wells were washed 3 times 
with TST buffer, pH 8.0 to remove unbound radioactivity. Each well was then cut 
out individually, placed in polystyrene tubes and the amount of radioactivity bound 
to the wells measured in a Berthold multihead gamma spectrometer. This procedure 
was carried out with antibodies 71, 75 and 42 in the 9 possible combinations. 
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2.4.2.2 Cellulose as Solid Phase 
Cellulose was activated using 1.1-carbonyldiimidazole which derivatises cellulose and 
hence enables coupling to antibody (Chapman et a/., 1983). 
Five grams of microparticulate cellulose (Sigmacell type 20, Sigma, London, UK) 
were activated by adding 1.1-carbonyldiimidazole (Sigma) (0.61 g/25 ml 0.15 mol// 
acetone) and the mixture vigorously stirred at room temperature for 1 hour. The 
activated imidazolyl carbamate cellulose was recovered by filtration over a glass 
microfibre filter (Whatman GF/A, retention efficiency 2 nm, Whatman Labsales 
LTD., UK), washed with three 100 ml portions of acetone, dried in air and stored 
in a tightly sealed container at -20 °C until required for protein coupling. 
Two hundred milligrams of activated cellulose and 4.5 mg of antibody in 3.0 ml 
borate buffer (0.1 mol// Na2B4O7.10H2O, pH 9.0) were vortex shaken to a slurry and 
then placed on a rotating shaker at room temperature for 16 hours. After the 
reaction, the protein remaining in solution was recovered by centrifugation (1200 g 
for 20 min) and the concentration in the supernatant measured by the method of 
Lowry et al. (1951). The percentage of protein coupled to cellulose was calculated 
by difference. The pellet was washed by centrifugation with 10 ml portions of several 
buffers in the sequence set out below: 
bicarbonate buffer (0.5 mol// NH4HC03, pH 8.0), rotated for 20 min; repeated; 
acetate buffer (0.1 mol// CH3COONH4, pH 4.0), rotated for 20 min; 
acetate buffer (pH 4.0) rotated 16 - 20 hours; 
phosphate buffer (0.067 mol//, pH 7.4, containing 1% BSA, 0.1% Tween-20 and 
0.1% sodium azide) rotated for 20 min; repeated. The cellulose-bound antibody was 
stored at 4°Cuntil required. 
One hundred microlitres of a suspension of cellulose-bound antibody in about 16 
volumes of phosphate buffer and 100 /xl free a-subunit (5 Mg/ml) in phosphate 
buffer were mixed and rotated overnight at room temperature. The NSB was 
measured by substituting 100 fil buffer for free a-subunit in one set of tubes. The 
incubate was centrifuged and the resulting pellet washed twice with 1.0 ml 
phosphate buffer (0.067 mol//, pH 7.4 containing 0.1% BSA, 0.1% Tween-20 and 
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0.1% sodium azide). This was followed by a further incubation with 100 /il [125I]-
labelled antibody to the a-subunit (approximately 100 000 cpm, section 3.4) for 8 
hours. After washing, the incubate was centrifuged at 3000 g for 10 min and the 
supernatant decanted and the tubes drained. Bound radioactivity in the cellulose 
pellet was counted in a Berthold gamma spectrometer. 
2.4.3 Statistics 
Each experiment was performed in quadruplicate and the significance of the 
differences in cpm, between the sample and NSB was tested by applying the 
unpaired t-test. 
2.4.4 Results and Comment 
The binding data of the three antibodies to the free a-subunit in a two-site assay in 
which the stationary medium was varied are presented in Table 2.2. 
There are a number of relevant observations arising from these results. Firstly, 
enhanced binding occurred with combinations of different antibodies, particularly 
antibodies 71 and 75, irrespective of which solid-phase was used. No further binding 
took place when the same antibody was used in combination. It can therefore be 
concluded that each antibody is directed at a separate epitope on the free a-subunit 
molecule. 
Secondly, binding of the free a-subunit to antibody 42, a relatively non-specific 
antibody (section 2.2.3) was generally very low. It would appear that antibody 42 
binds at an epitope which may be near the epitopes of antibodies 71 and 75 and 
thus sterically interferes with binding. Alternatively, tertiary structural changes in the 
free a-subunit after binding to antibody 42 may obscure the epitopes for antibodies 
71 and 75. In either event, antibody 42 is manifestly unsuitable for use in a two-
site assay with either antibodies 71 and 75. 
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Table 2.2 Bound radioactivity measured in cpm after simultaneous incubation of 

































Results shown indicate the difference in cpm between 500 ng and 0 ng of free a-
subunit (NSB); * indicates a significant difference (p < 0.05). 
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By contrast antibodies 71 and 75 function exceptionally well in a two-site assay. It 
seems immaterial whether they are used as liquid or solid-phase antibodies, nor does 
the nature of the solid-phase seem to have any effect on the binding efficiency. 
2.5 ASSESSMENT OF COOPERATIVE BINDING 
The possibility of the phenomenon of cooperative binding occurring with the 
antibodies raised in this study was examined by comparing the binding following 
simultaneous incubation of free a-subunit with antibodies 71 and 75 or antibody 75 
and a non-specific antibody in a radioimmunoassay (RIA). 
2.5.1 Principle 
The ability of two antibodies which bind two distinct epitopes on an antigen to form 
a circular complex resulting in enhanced affinity and sensitivity of measurement, is 
referred to as cooperative binding (Moyle et al., 1983b). 
2.5.2 Materials and Method 
Antibody 75 coupled to cellulose (section 2A.1.2) was diluted 100 fold in assay buffer 
(phosphate 0.067 mol/7, 0.1% BSA, 0.01% Tween-20; pH 7.4). One hundred 
microlitres of diluted antibody were incubated for 4 hours at 37 °C with 100 jul of 
[125I]-labelled free a-subunit (approximately 30 000 cpm) or buffer as NSB. Various 
dilutions (1/6 to 1/768) of antibody 71 in 100 /xl portions or the mouse monoclonal 
antibody 2/6 (which recognises the J3-subunit of hCG but not a-subunit) as control 
were then added and further incubated for 4 hours at 37°C.The incubates were 
centrifuged and the pellet washed once with assay buffer. After centrifugation the 
radioactivity in the pellets was counted. 
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2.5.3 Results and Comments 
Results shown in Table 2.3 indicate that the addition of a specific second monoclonal 
antibody, in this case antibody 71, led to a higher binding of the free a-subunit by the 
solid-phase-bound antibody 75 when compared to the addition of the 'non-specific' 
monoclonal antibody 2/6 as control. 
It would appear therefore that antibodies 75 and 71 display cooperativity in binding 
to the antigenic molecule, that is, addition of 71 to an incubate of radiolabeled a-
subunit bound to 75 induced further binding of the a-subunit (up to 250% at certain 
dilutions of antibody). This enhancement in binding may be explained by the 
phenomenon of circular complex formation described by Moyle et al. (1983b). The 
binding of the second specific antibody to the antigen is thought to induce circular 
complexes which render the epitopes present on the antigen molecule more 
accessible to further binding with the solid-phase antibody. Using the proposals of 
Moyle et al. (1983a) a possible structure for such a circular complex is illustrated in 
Fig 2.5. 
2.6 SUMMARY 
Two monoclonal antibodies 71 and 75 were characterised with respect to specificity, 
affinity for the a-subunit, ability to recognise different epitopes and display co-
operativity in binding. A comparison was made with the published data on a third 
monoclonal antibody (antibody 42). Antibodies 71 and 75 showed a high degree of 
specificity for the free a-subunit, implying that they recognise epitopes hidden by the 
folding of the 6-subunit in the intact dimeric protein. Antibody 42 appeared to 
recognise an epitope that was preferentially exposed on the intact molecule of hCG, 
TSH, FSH and LH since the cross-reaction of this antibody with the intact hormone 
was greater than that with the isolated a-subunit. 
Both antibodies 71 and 75 showed comparatively low affinities for the a-subunit 
molecule, with dissociation constants of 0.92 x 10~8 and 4.08 x 10"8 mol//, respectively. 
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Table 2.3 Bound radioactivity measured in cpm after the incubation of a second 






























* Results are shown as radioactive counts after precipitation of the pellet (results in 







Figure 2.5 Circular complex formation of antibodies 71 and 75 with two 
molecules of the free a-subunit. This diagram represents a possible 
circular complex that is proposed to be responsible for the binding 
enhancement observed in some mixtures of monoclonal antibodies. 
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Pairwise combinations of the three antibodies were shown to bind simultaneously to 
the a-subunit, indicating that they recognise three distinctly different epitopes on the 
molecule. The two antibodies 71 and 75 displayed cooperativity in binding as 




THE DEVELOPMENT OF AN IMMUNORADIOMETRIC ASSAY FOR 
THE MEASUREMENT OF FREE ALPHA-SUBUNIT OF HCG 
Good methods can teach us to develop and use to better purpose the faculties 
with which nature has endowed us, while poor methods may prevent us from 
turning them to good account. Thus the genius of inventiveness, so precious 
in the sciences, may be diminished or even smothered by a poor method, 
while a good method may increase and develop it. 
Claude Bernard [1813 - 1878] 
3.1 INTRODUCTION 
The use of monoclonal antibodies in the immunoradiometric assay (IRMA) format 
(Norman et al., 1985), has led to greatly increased sensitivity and specificity in a 
variety of hormone assays. This chapter describes the development of an IRMA for 
the measurement of free a-subunit of hCG using monoclonal antibodies raised and 
characterised as described in chapters 1 and 2. 
3.1.1 Principle 
In the commonly used two-site IRMA, the antigen becomes 'sandwiched' between 
two antibodies that are directed against distinct and sterically distant epitopes. One 
antibody, called the 'capture antibody', is usually bound to a solid phase matrix 
(plastic, cellulose, etc.) and its concentration exceeds that of the antigen. This 
antibody binds to the antigen in amounts proportional to the concentration of the 
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antigen in the sample to be analysed. The bound antigen is subsequently detected 
by a second antibody, designated the 'detection antibody', which carries a label such 
as a radioactive isotope or an enzyme. 
3.1.2 Choice of Method 
An ideal assay procedure is one which is simple, robust, specific and highly sensitive 
with a wide working range. The classical two-site IRMA is a two step procedure in 
which the first incubation step involves extraction of the antigen with a solid-phase 
coupled antibody and the second allows binding of radiolabeled antibody with the 
coupled antigen. The use of monoclonal antibodies in the IRMA format offers the 
advantage of increased specificity for the antigen. In addition, use of a solid-phase 
medium for separation, and a capture antibody in excess, provide for optimal binding 
of analyte and thorough washing at the separation stage. Both these factors are 
advantageous in providing high sensitivity, at least 3 orders of magnitude higher than 
in RIAs, and a wide assay working range. 
Odell et a/.(1986) described a unique assay design that is both simple and of greater 
sensitivity than the common IRMA. This assay procedure uses polystyrene beads 
and the avidin-biotin reaction as a solid-phase separation system. The capture 
antibody labelled with biotin is initially in the liquid phase and is thus a modification 
of the conventional two-site assay. The design of the IRMA is shown in Fig 3.1 which 
schematically represents a polystyrene bead coated with BSA, biotinylated BSA and 
avidin after incubation with biotinylated capture antibody, free a-subunit and 
radiolabeled detection antibody. 
Biotin has a high affinity (K„ = 10"15 mol/7) for avidin and the reaction between the 
two molecules results in the formation of a very stable avidin-biotin complex. Avidin 
has four binding sites; when used in a two-site IRMA it acts as a bridge between 
two biotinylated reagents (eg. biotinylated BSA and biotinylated first or capture 
antibody) linking both antibodies and analyte to solid-phase. The two remaining sites 
on the avidin provide additional amplification and allow for further binding of 
capture antibody to solid-phase. 
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_ x o - 125i M Biotin 
0 
Antibody <(%Avidin 
Free a-subunit — Glutaraldehyde 
BSA 
Figure 3.1 Schematic representation of a polystyrene bead coated with BSA, 
biotinylated BSA and avidin after incubation with biotinylated 
antibody, free a-subunit and radiolabelled antibody. 
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The ease with which BSA can bind to polystyrene, the affinity and specificity with 
which biotin binds to avidin and the ease with which biotin binds to any protein has 
been utilised to provide a solid-phase support that is both simple and reliable. In 
addition thorough washing of the solid-phase after the incubation period is a simple 
matter so that the precision and sensitivity of the assay can be fully exploited. 
Centrifugation is not required and the polystyrene bead therefore provides a simple 
method of separation. 
The various procedures involved in the establishment of the IRMA are described 
in the following sections. 
3.2 PREPARATION OF SOLID PHASE COMPONENTS 
Careful selection of the solid phase and optimisation of the method of separation 
is essential in the overall design of an IRMA. The procedures involved in the 
preparation of the solid phase components and optimisation of the separation system 
are discussed in this section. 
3.2.1 Coating of Polystyrene Beads 
The technique used for coating of the polystyrene beads with biotin-avidin is 
essentially that described by Odell et al. (1986). 
Two thousand polystyrene beads (8 mm in diameter, Precision Plastic Ball Co., 
Illinois, USA) were washed several times with distilled water (dH20), before being 
added to 600 ml of phosphate buffered saline (PBS) containing 0.1% BSA and 
shaken gently for two hours. The beads were rinsed once with dH20 and allowed to 
stand in 600 ml of a 1% glutaraldehyde solution (BDH, U.K.) for 24 h to allow 
linkage between the BSA molecules. They were then washed 10 times with dH20 
and incubated for 6 - 8 h in 600 ml of PBS containing 20 mg of biotinylated BSA 
(the biotinylation procedure is described in section 3.2.2.2.2). After washing, the 
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beads were incubated with 600 ml PBS containing 1% BSA and 20 mg of streptavidin 
(Amersham) or avidin (Boehringer Mannheim, W. Germany). The beads were rinsed 
with dH20 and finally incubated with PBS containing 0.1% BSA and 0.25% sucrose 
for 20 min. The coated beads (hereafter referred to as beads coated with avidin) 
were then spread on absorbent paper and allowed to dry thoroughly. The dried beads 
were stored in plastic containers in liquid nitrogen. 
3.2.1.1 Comment 
Streptavidin, a cell wall protein from Streptomyces avidinii, has been suggested in the 
literature as an alternative to avidin (Haeuptle et al, 1983; Mayer and Walker, 1987). 
It has similar binding properties to avidin and is believed to have an added 
advantage in minimising background binding. There was however no change in the 
NSB of the assay when streptavidin was substituted for avidin in the coating 
procedure (results not shown) and avidin was therefore used for further coating of 
beads in this study. 
The reproducibility of the coating of the polystyrene bead was carefully assessed for 
each new batch of solid-phase. When a new batch of coated beads was required, it 
was prepared as described and compared in the IRMA, using standards, to the 
previous lot. This was essential to the reproducibility of the assay. 
3.2.2 Preparation of Biotinylated Antibody and BSA 
The co-enzyme biotin is a relatively polar molecule and is coupled with high affinity 
to proteins under very mild conditions with little disruption to their structure. Before 
it can be coupled to protein, however, it must be derivatised to allow formation of 
stable amide bonds under very mild conditions. The most convenient method of 
coupling uses the N-hydroxysuccinimide ester of biotin (Bayer and Wilcheck, 1974; 
Bayer et al., 1979). Both antibody 75 and BSA were labelled with biotin using the 
Enzotin reagent which is a commercially available N-hydroxysuccinimide ester of 
biotin. The degree of biotinylation of the antibody preparation was assessed using a 
method recommended by the manufacturer of the Enzotin reagent. 
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3.2.2.1 Principle 
The mechanism of coupling of biotin to protein involves the activated ester of biotin 
and the nucleophilic unprotonated e-amino groups of the lysine residues on the 
protein, resulting in the formation of an amide bond and release of N-
hydroxysuccinimide (as shown in Fig. 3.2). Succinimide esters are very prone to 
hydrolysis, and during coupling there is a competing hydrolytic reaction. The extent 
to which coupling and hydrolysis compete depends on the protein concentration. At 
high concentrations ( 1 - 1 2 mg/ml), the coupling reaction is quite efficient while at 
low concentrations (< 1 mg/ml), the competing hydrolysis reaction predominates. 
The method used to determine the degree of biotinylation takes advantage of the 
fact that biotin reacts under anhydrous conditions with p-
dimethylaminocinnamaldehyde in sulphuric acid-ethanol to produce a reddish-orange 
colour which is maximally absorbed at 533 nm. The ureido carbonyl function is a 
prerequisite for colour response and the stereospecificity of the colour reaction is for 
the sulphur end of biotin (McCormick and Roth, 1970). 
3.2.2.2 Materials and Methods 
3.2.2.2.1 Buffers and Reagents 
i. Phosphate Buffered Saline (PBS) 
130 mmol/7 NaCl 
7.0 mmol/7 Na2HP04 
2.6 mmol// NaH2P04.H20 
pH 7.4. 
ii. p-dimethylaminocinnamaldehyde (DMAC) Solution 
DMAC (200 /ig) [Sigma] was dissolved in 100 ml of 2% (v/v) concentrated H2S04 
in ethanol. 
3.2.2.2.2 Biotinylation Procedure 
The protein solution (antibody 75 or BSA) was dialysed (using Spectrapor dialysis 
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Figure 3.2 Structure of biotin and its succinimide ester (biotin-NHS), and the 
mechanism of coupling to proteins. 
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1800 ml of 0.1 mol// NaHC03 and the protein concentration adjusted to between 2 
and 5 mg/ml with 0.1 mol// NaHC03. The Enzotin reagent (Biochem Incorporation, 
New York, USA) was dissolved in dimethyl sulphoxide (DMSO) at the same 
concentration (mg/ml) as the protein. Enzotin (120 ixl / ml protein solution) was 
added, mixed immediately, and incubated for 4 h at room temperature. After 
incubation, the solutions were dialysed (as described previously) against 2 / PBS 
overnight at 4 ° C. 
3.2.2.2.3 Determination of Degree of Biotinylation 
Portions containing between 0.2 and 0.5 mg of biotinylated protein were added to 
an equal volume of concentrated HC1 in a glass ampoule which was then sealed. 
The contents were heated in boiling water for 2 h and thereafter lyophilised. Another 
ampoule containing an equal amount of unbiotinylated protein or BSA was prepared 
as a blank. 
Standards were prepared by dissolving the Enzotin reagent to a concentration of 1 
mg/ml in dimethylformamide (DMF). Portions (ranging between 1 and 100 /xl) of 
this solution were added in duplicate to the glass ampoules and lyophilised. To each 
ampoule 200 /xl unbiotinylated protein or BSA (0.2 - 0.5 mg) were added. 
Concentrated HC1 (200 >u.l) was then added and ampoules sealed. The contents were 
heated in boiling water for 2 h and then lyophilised. 
The samples, standards and blank were redissolved when required in 800 /xl of 2% 
concentrated H2S04 in ethanol (v/v). One hundred microlitres of the chromogen 
(DMAC solution) were added to each ampoule followed by incubation for 1 h at 
room temperature. 
The absorbances at 533 nm were read against unbiotinylated protein or BSA using 
a Beckman DU5 Spectrophotometer. A standard curve of absorbance against the 
amount of Enzotin was then plotted and used to determine the degree of 
biotinylation of the BSA and antibody. 
3.2.2.2.4 Assessment of Binding of Each Biotinylated Antibody Preparation 
Antibody 75 was labelled with varying amounts of Enzotin reagent (120, 240 and 
57 
360 /il) as described in section 3.2.2.2.2. Each preparation of biotinylated antibody 
75 (50 /ill) in concentrations ranging from 2 to 80 Mg/ml phosphate buffer (0.067 
mol/Z with 0.1% BSA, pH 7.4) was incubated with 150 /xl ( about 1 x 105 cpm) 12SI 
labelled free a-subunit (see section 3.4) and a polystyrene bead coated with avidin 
(as described in section 3.2.1) on a rotating mixer for 2 h at room temperature. The 
bead was washed twice with phosphate buffer (0.067 mol//, 0.2% Tween-20, pH 7.4) 
and the bound radioactivity counted in a Berthold multihead gamma spectrometer. 
The preparation of biotinylated antibody exhibiting maximal binding with free a-
subunit was determined. 
3.2.2.3 Results and Comment 
3.2.2.3.1 Degree of Biotinylation 
A standard curve relating the optical density readings at 533 nm to the amount of 
Enzotin (biotin ester) in micrograms is shown in Fig. 3.3. 
After determining the amount of biotin which bound to antibody 75 from this curve, 
the ratio of unbiotinylated protein to biotin was calculated as shown in the following 
example: 
molecular weight of antibody = 150 000 daltons 
molecular weight of biotin ester = 454 daltons 
Initial concentration of antibody = 2.5 mg/ml 
Concentration of biotin ester = 2.5 mg/ml 
Volume of biotin ester solution added = 120 jiil 
Final concentration of protein mixture = 2.5/1.12 = 2.2 mg/ml 
250 /xl (0.55 mg) of biotinylated antibody solution was used in the assessment. 
Therefore moles of biotinylated antibody = 550/150 000 
= 0.004 Mmol 
The absorbance of the chromogen labelled biotinylated protein was read at 533 nm. 
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Figure 3.3 
biotinylation. 
Standard curve for the estimation of the degree of protein 
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Therefore moles of biotin ester (Enzotin) = 29/454 = 0.064 /Ltmol 
Molar ratio of protein to biotin after labelling = 1:16 
Similarly, the molar ratios of protein to biotin after the addition of increasing 
amounts of biotin ester in volumes of 240 and 360 /ul were calculated as 1:21 and 
1:29 respectively. 
The possibility of conjugating several biotin molecules to each antibody has an 
obvious benefit in increasing the sensitivity of detection. However, overbiotinylation 
may lead to masking of the antigen-binding site, and hence inactivation of the 
antibody. 
3.2.2.3.2 Assessment of Binding of Each Biotinylated Antibody Preparation 
The three samples of antibody 75 labelled with different amounts of biotin (120, 240 
and 360 MO showed varying degrees of binding to the [125I]-labelled free a-subunit 
(Fig. 3.4). The diluted preparation of antibody 75 labelled with 120 /xl biotin per ml 
antibody showed highest overall binding with the radiolabeled a-subunit. The 10 
Mg/ml concentration of this preparation exhibited maximal binding and this 
concentration was therefore chosen for further use. 
When determining the degree of biotinylation, that is the substitution of amino 
groups in the antibody molecule by biotin or the number of moles of biotin bound 
to each mole of antibody 75, it was found to be increased with increasing amounts 
of biotin ester (section 3.2.2.3.1). However, in the assessment of each preparation, 
it was found that the antibody binding capacity was decreased with more extensive 
substitution of amino groups by biotin; 120 /xl biotin per ml antibody showed maximal 
binding with the range of standards used. This volume of biotin ester preparation per 
ml of protein is generally recommended for labelling of proteins (Goding, 1986). 
In determining the optimal biotinylated antibody concentration, it was found that 
high concentrations of antibody inhibited binding, demonstrating the high dose 'hook' 
effect, a phenomenon very common to IRMAs (Hunter et al., 1983). To overcome 
this problem, the labelling procedure was optimised to preserve antigen binding 
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Antibody preparation labelled with 120 pi biotin/ml protein 
Antibody preparation labelled with 240 jul biotin/ml protein 

















Concentration of Biotinylated Antibody in pg/ml 
100 
Figure 3.4 Antibody concentration curves for the various preparations of 
biotinylated antibody 75. 
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capacity while maintaining maximal sensitivity. 
3.3 ALPHA-SUBUNIT STANDARDS 
Standards were prepared from lyophilised free a-subunit (1st International Reference 
Preparation [IRP] 75/569, a gift from the World International Laboratory for 
Biological Standards, Holly Hill, UK) by dissolving 70 jug in 1.0 ml of phosphate 
buffer (0.067 mol//, pH 7.4). Portions (40 jul) of this solution (master standard) were 
then stored at -20°Cuntil use, at which time 32.5 jul were diluted with 7 ml undiluted 
horse serum to give a stock solution of 323 ng/ml. The stock solution was 
appropriately diluted in horse serum to prepare a set of standards as shown in the 
Table 3.1. The standards were divided into portions of 300 /il and stored at -20 °C 
until use. 
A reference preparation was required for the measurement of the free a-subunit of 
hCG because this component is not a single, chemically-defined substance. This 
material was prepared from the CR123 preparation of intact hCG by hydrogen bond 
cleavage with urea and separation by ion exchange chromatography (Morgan et ai, 
1973). Although it possesses no intrinsic bioactivity, the a-subunit has been assigned 
a unit value per unit mass (1 mlU = 1 ng). However, for the purpose of the present 
study it was elected to express concentrations in terms of mass per unit volume. 
Where molar concentrations have been used, these values were calculated using an 
assigned molecular weight of 15 000 daltons for free a-subunit (Bellisario et al., 
1973). 
Standards were initially prepared in phosphate buffered saline but subsequently 
standards were prepared in undiluted horse serum to improve the sensitivity of the 
assay (section 3.6.1.1). 
The standards were found to be stable at -20°Cfor at least 6 months. When a new 
batch of working standards was required, this was prepared from the master standard 
as described above and compared to the preceding batch. The intra-and inter-assay 
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coefficients of variation between two batches of standards were required to be less 
than 10% over the range of standards used in the assay. 
3.4 PREPARATION OF RADIOLABELLED ANTIBODY 
The detection antibody 71 was radioiodinated by the Chloramine T method 
(Greenwood et al., 1963). 
3.4.1 Principle 
Under mild alkaline conditions free 125I released from [12TJ-NaI by an oxidising agent 
(Chloramine T), forms a covalent bond with tyrosine residues in the protein 
molecule. The oxidation reaction is terminated by the addition of a reducing agent 
(sodium metabisulphite) or alternatively, excess tyrosine, and quenched with buffer 
containing high concentrations of protein. The iodinated protein is isolated by gel 
filtration. 
3.4.2 Materials and Methods 
3.4.2.1 Buffers 
i. 0.067 mol/l Phosphate Buffer, pH 7.4 
Solution A = 0.067 mol/l KH2P04 
Solution B = 0.067 mol/l Na2HP04.2H20 
The pH of solution B was measured while adding solution A until a pH of 7.4 was 
obtained. Sodium azide was added to the buffer at a final concentration of 0.1%. 
Hereafter referred to as phosphate buffer 1. 
ii. 0.33 mol/l Phosphate Buffer, pH 7.4 
Solution A = 0.33 mol/l KH2P04 
Solution B = 0.33 mol/l Na2HP04.2H20 
The pH of solution B was measured while adding solution A until a pH of 7.4 was 
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obtained. Sodium azide was added to the buffer at a final concentration of 0.1%. 
3.4.2.2 Reagents 
i. Chloramine T Solution 
Chloramine T (100 mg; Merck) was dissolved in 40 ml of phosphate buffer 1, 
pH 7.4, to give a concentration of 2.5 Mg/ml. 
ii. Sodium Metabisulphite Solution 
One hundred milligrams of sodium metabisulphite (Merck) were dissolved in 16 ml 
of phosphate buffer 1, pH 7.4 to give a concentration of 6.25 Mg/ml. 
3.4.2.3 Preparation of Sephadex G100 Column 
Deaerated Sephadex G100 (Pharmacia) in phosphate buffer 1 was poured into a 25 
x 1 cm glass column. The column was packed and two volumes of buffer were 
washed through the column before use. 
3.4.2.4 Iodination Procedure 
Antibody 71 (40 Mg), 5/xl of phosphate buffer (0.33 mol/l, pH 7.4), 18.5 MBq in 5 
jul of [125I] sodium iodide solution (specific activity approximately 548 MBq/jUg, 
Amersham) and 5 i±\ (2.5 Mg/ml) of Chloramine T solution were added to a 
microfuge vial and mixed gently for 20 seconds. Five microlitres (6.25 Mg/ml) of 
sodium metabisulphite solution were then added to the iodination vial and mixed 
for 1 minute. The reaction was quenched by the addition of 75 M1 of phosphate 
buffer 1 containing 1% BSA. 
The final solution was applied to the Sephadex G100 column and eluted with 
phosphate buffer 1 at a flow rate of 5 ml/h. Fractions of 500 M1 or 10 drops/tube 
were collected and the radioactivity counted in a multihead gamma spectrometer 
(Berthold). The radioactive fractions (antibody peak) eluting after the void volume 
were pooled, suitably diluted with phosphate buffer 1 and assayed for antibody 
activity. 
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3.4.2.5 Assessment of Labelled Antibody 
Fifty microlitres of labelled antibody 71 (approximately 200 000 cpm) were incubated 
with 50 iA (0.5 /xg) of biotinylated antibody 75, 100 ji\ of the various a-subunit 
standards or undiluted horse serum (as blank) and one avidin-coated bead on a 
rotating mixer for 2 h at room temperature. After incubation the bead was washed 
twice with 2 ml of phosphate buffer 1 containing 0.2% Tween-20 and the bound 
radioactivity counted as above. This assay is described in greater detail in sections 3.5 
and 3.6. 
3.4.2.6 Calculation of Specific Activity of Radiolabelled Antibody 
The percentage of 125I incorporated by the antibody was determined as follows: 
% Incorporation = Bound 12SI x 100 
(Bound + Free) 125I 
= cpm in 125I antibody peak x 100 
cpm in 125I antibody peak + cpm in free 12SI peak 
The specific activity per unit mass of radiolabelled antibody was then calculated as 
follows: 
specific activity = % incorporation x xMBq x y 
mass (jug) 
where x is the amount of radioactivity added and y is the decay factor. 
3.4.3 Results and Comment 
Because Chloramine T is a harsh oxidising agent, care was taken to ensure precise 
timing of the iodination reaction. Incorporation generally exceeded 90% when 
relatively high concentrations of protein were used (> 1.0 mg/ml). Purification of the 
radiolabelled preparation revealed two radioactive peaks, with the larger antibody 
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Figure 3.5 Radioactive peaks obtained after purification of radiolabelled 
antibody preparation by gel filtration on Sephadex GlOO. 
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An equimolar ratio of 12SI and antibody was chosen for use in the iodination reactions 
to achieve an average substitution of approximately one iodine atom per molecule 
of protein, as illustrated in the following example: 
moles of antibody (40 izg, mw 150 000 daltons) = 0.27 nmol 
moles of 125I (18.5 MBq at specific activity of 548 MBq/^g) 
= 18.5 MBq = 0.27 nmol 
548 MBq//jg x 125 
The equimolar ratio was adopted because antibody preparations of low specific 
activity have a high proportion of unlabelled antibody which decreases assay 
sensitivity while in preparations of high specific activity, increased sensitivity is 
achieved at the cost of increased radiation damage. 
The specific activity of the radiolabelled antibody was generally calculated to be 
about 420 MBq / ^g of antibody. The radiolabelled antibody demonstrated good 
immunoactivity, the highest standard showing an average percentage binding •-. f 60% 
for up to 4 weeks when stored in phosphate buffer 1 with 0.1% BSA at 4°C. 
3.5 IRMA PROCEDURE 
Using the various reagents which have been prepared as described, the IRMA for 
the free a-subunit was empirically designed as follows: 50 ng biotinylated antibody 
75 in 50 i±\ phosphate buffer 1, radiolabelled antibody 71 in the same buffer (50 zzl; 
approximately 200 000 cpm) and 100 /zl of free a-subunit standard diluted in PBS 
(pH 7.4) were incubated in a test tube containing an avidin-coated bead at room 
temperature on a rotating shaker for 2 h. PBS (100 jul) was assayed as an assessment 
of non-specific antibody (NSB). After incubation, the solution was aspirated and the 
bead washed twice with 2 ml phosphate buffer 1 containing 0.2% Tween-20 (Merck). 
The radioactivity on each bead was counted for 1 min in a gamma spectrometer. 
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3.6 EVALUATION OF THE IRMA 
Having developed an IRMA for the measurement of free a-subunit, the next step 
was to examine systematically the various stages of the assay procedure for the 
purpose of optimising the assay conditions for sensitivity, specificity, precision and 
accuracy. 
When evaluating the merits of the assay procedure it is imperative to define certain 
concepts. The sensitivity of an assay is defined as that concentration of analyte which 
gives a level of bound radioactivity equivalent to the mean NSB plus two standard 
deviations above the mean in any individual assay system. The specificity of a 
monoclonal antibody-based IRMA for an antigen is defined by the specificities of the 
antibodies for epitopes which are unique to that particular antigen and is usually 
determined by assessing cross-reaction with related molecules. The precision of an 
assay refers to the reproducibility of the results, usually assessed by determining the 
standard deviation of replicate measurements of the same sample within an assay 
(intra-assay precision) or between assays (inter-assay precision). Good sensitivity is 
therefore dependent on both a low NSB and precise measurement of the NSB. 
In the following section, various aspects of the assay procedure which are important 
determinants of the assay sensitivity, specificity, precision and accuracy are examined 
and described in detail. 
3.6.1 Materials and Methods 
3.6.1.1 Assay Optimisation 
3.6.1.1.1 Effect of Protein on Binding and Sensitivity 
The effect of various protein solutions as assay diluents on NSB was examined with 
a view to optimising assay sensitivity. PBS (pH 7.4) as well as PBS containing 0.1% 
BSA, serum from a patient with panhypopituitarism, serum from a pregnant patient 
and horse serum were assayed in the IRMA. In addition, free a-subunit standards 
ranging in concentrations from 0.05 - 0.8 ng/ml were prepared in PBS with 0.1% 
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BSA, horse serum and serum from a patient with panhypopituitarism respectively, 
and assayed in the IRMA. The effect of these protein solutions on binding and 
sensitivity was assessed by means of dose response curves and by applying the z-test 
for each solution. 
3.6.1.1.2 Effect of Sequential Incubation on Binding and Sensitivity 
To examine the effect of sequential incubation of antibodies, free a-subunit standards 
(100 /ul) diluted in horse serum and ranging in concentrations from 0 -32 ng/ml were 
incubated for 1 hour with avidin coated beads (1 bead/tube) and 100 IJL\ biotinylated 
antibody 75 (10 /ig/ml). After incubation, each bead was washed once with 
phosphate buffer 1 containing 0.2% Tween-20, the second radiolabelled antibody 
(200 /Ltl, approximately 200 000 cpm) added and the tubes incubated for a further 
1 h. The beads were then washed once with phosphate buffer 1 with 0.2% Tween-
20 and the bound radioactivity counted in a gamma spectrometer. 
Concurrently, an assay with simultaneous incubation of antibodies using horse serum 
as assay diluent was also carried out. 
The specific binding at different concentrations of standard were compared by dose 
response curves and the sensitivity of each assay determined by applying the z-test. 
3.6.1.1.3 Effect of Incubation Time on Assay 
The assay was carried out as described in section 3.5 but varying incubation times 
of 1, 2, 4, 24 or 72 h and horse serum as assay diluent were used. The effect on 
assay binding at various standard concentrations and the sensitivity of the assay with 
increasing incubation time was determined. 
3.6.1.1.4 Effect of Sample Volume on Assay Sensitivity 
The effect of increasing incubation volumes on sensitivity was studied by assaying 
a-subunit standards diluted in horse serum, in concentrations ranging from 0.0125 -
0.2 ng/ml in volumes of 100-1000 /ul, as described in section 3.5. The sensitivities of 
the assays using different sample volumes were compared by applying the z-test. 
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3.6.1.1.5 Effect of Washing on Binding, Precision and Sensitivity 
The assay was carried out as described in section 3.5 except that the beads were 
washed once, twice or three times with phosphate buffer 1 containing 0.2% Tween-
20 and horse serum was used as an assay diluent instead of PBS. The effect of 
washing on the NSB and the precision in the measurement of standards in the assay 
were then assessed. 
3.6.1.2 Characteristics of the IRMA 
After establishing the optimal assay conditions for the measurement of the free a-
subunit, the IRMA procedure described in section 3.5 was suitably modified and 
then characterised with respect to its dose response curve, sensitivity, specificity and 
working range. 
3.6.1.2.1 Dose Response Curve 
A dose response curve was constructed by plotting the specific bound radioactivity 
measured in cpm against the free a-subunit concentration. 
3.6.1.2.2 Sensitivity and Precision 
Using the optimal assay procedure, the sensitivity of the assay was assessed by 
determining the lowest free a-subunit standard concentration which gave a level of 
bound radioactivity that was equivalent to or greater than the mean NSB + 2 SD 
above the mean. Intra-assay variation was assessed in a precision dose profile by 
quadruplicate assay of standards at concentrations ranging from 0 - 3 2 ng/ml, and 
inter-assay variation by the assay of the same standards in four separate assays. 
Precision was expressed as the percentage coefficient of variation (%CV) of intra-
and inter-assay results. 
3.6.1.2.3 Working Range 
To determine the optimal concentration range of antigen over which the assay can 
be used, a serum sample with high concentrations of free a-subunit (32 ng/ml) was 
serially diluted to about 0.03 ng/ml in horse serum and assayed in the optimised 
IRMA. Expected-to-measured free a-subunit concentrations were compared and the 
optimal working range for serum determined. 
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3.6.1.2.4 Assay Specificity 
To determine assay specificity for free a-subunit, standards of free a-subunit of hCG 
(1st IRP), free 6-subunit of hCG (1st IRP), intact hCG, LH, FSH and TSH (2nd 
IRP) were assayed in the optimised IRMA. The degree of cross-reaction was 
determined by calculating the ratio (mass/mass) of cross-reacting material to free 
a-subunit which yielded equivalent binding to labelled antibody. Cross-reactivity was 
expressed as a mass ratio rather than a molar ratio for purposes of comparison with 
the literature. 
Contamination of the FSH standard by the free a-subunit has been reported by 
Thotakura and Bahl (1985). It was therefore necessary to purify the standard to 
determine its true cross-reaction in the free a-subunit IRMA. One ml of FSH 
standard (5 x 104 IU/1), dextran blue, [125I]-FSH (100 nl, Amersham FSH kit) and 
[125I]-free a-subunit (100 MO were premixed and applied to a column of Sephadex 
G100 (Pharmacia; 450 x 15 mm) equilibrated with phosphate buffer 1. The column 
was eluted with the same buffer at a downward flow rate of 8 ml/h and fractions of 
1.1 ml collected. All fractions were assayed for FSH by a commercial RIA 
(Amersham) and for free a-subunit by the IRMA. The percentage of free a-subunit 
contamination contributing to FSH cross-reaction (mass/mass) was determined by 
calculating the areas under the respective curves as measured in the free a-subunit 
IRMA. True cross-reaction was determined by comparing free a-subunit 
immunoreactivity with the FSH concentration in the fractions eluting with [125I]-FSH. 
3.6.2 Statistics 
The z-test was applied to compare statistically the effect of related parameters on 
the sensitivity of the IRMA (Rimm et al., 1980). Using this method, the actual 
measurements can be converted to a standard scale. The method assumes that if the 
total area under the normal distribution curve is 1.00 (100%), then it is possible to 
use the curve in a probabilistic manner. The standard normal distribution, denoted 
by z, has a mean equal to 0 and standard deviation equal to 1. To calculate an area 
under the normal distribution curve, the actual measurements are converted to a 
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corresponding point z on the z scale, using the following formula: 
z = x2 - xl / SD, 
with x2 referring to the lowest standard mean, xl referring to the NSB mean and 
SD to the standard deviation of the NSB duplicates. This formula expresses the 
mean value of the standard as being a specified number of standard deviation units 
from the mean NSB value. A value of z > 2 (which implies p <_ 0.05) indicates 
significant sensitivity and the highest z value indicates the best sensitivity. 
The precision of replicate sample measurements was expressed as the percentage 
coefficient of variation (%CV) which was calculated by dividing the standard 
deviation (SD) by the mean value and then multiplying by 100. 
The non-parametric Signed Rank test was applied to determine the significance of 
the differences in binding between pairs of the same samples, tested under varying 
assay conditions. When multiple comparisons were made (> 2), the significance level 
was adjusted by dividing the p value by the number of variables assessed (Bonferroni 
adaptation). 
3.6.3 Results and Comments 
3.6.3.1 Optimisation of the IRMA 
3.6.3.1.1 Effect of Protein on Binding and Sensitivity 
Table 3.2 shows the NSB (cpm mean and SD) and calculated assay detection limit 
(mean NSB + 2SD) for each assay diluent tested. Horse serum demonstrated the 
lowest NSB and assay detection limit (NSB + 2SD). 
The sensitivity of the IRMA when various protein solutions were used to dilute to 
the lowest standard (0.05 ng/ml) is shown in Table 3.3. Horse serum was found to 
give the highest z value and hence the best sensitivity. Fig. 3.6 shows the dose 
response curves when these protein solutions were used to dilute the free a-subunit 
standard. The percentage specific binding of standards diluted in horse serum was 
not significantly higher over the range of standards used, compared to those diluted 
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* indicates the assay diluent giving the lowest assay detection limit (mean + 2SD). 
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Table 3.3 Binding observed following dilution of the lowest free a-subunit standard 
with various protein solutions. 
Protein solution 























(1) z = -5.1 
(2) z = 7.6 
(3) z = 0.9 















PBS with 0.1 % BSA with NSB of 2.4 % 
Horse serum with NSB of 0.1 % 
Hypopituitary serum with NSB of 0.3 % 
0.05 0.1 0.2 0.4 
Concentration of free a-subunit standard in ng/ml 
0.8 
Figure 3.6 Dose response curves for a-subunit in the IRMA following dilutions 
with various protein solutions. 
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in serum from a patient with panhypopituitarism. Horse serum gave the best 
sensitivity and was therefore chosen for use as an assay diluent in the preparation 
of standard and control samples. 
The choice of an appropriate diluent for the assay standards is important for optimal 
assay performance because it affects the NSB and therefore the sensitivity of assay. 
Solutions containing protein are commonly used, although the ideal matrix for a 
standard is the same as the sample to be tested. Although serum from patients with 
panhypopituitarism is most suitable as matrix when measuring free a-subunit the 
limited availability necessitated the search for a reliable substitute. Horse serum was 
found in this study to serve as an appropriate matrix. The use of horse serum as 
supporting matrix for assay standards is well documented by other workers (Bolton 
and Hunter, 1986; Odell and Griffin, 1987). 
3.6.3.1.2 Effect of Sequential Incubation on Binding and Sensitivity 
A comparison of the effects of simultaneous and sequential incubation of antibodies 
on sensitivity of the assay is shown in Table 3.4. The assay sensitivity was enhanced 
when both antibodies and analyte were incubated simultaneously. The percentage 
binding at free a-subunit concentrations of 0.05 - 6.4 ng/ml was significantly higher 
(p = 0.03) as illustrated by the dose response curves (Fig.3.7). 
The enhanced binding observed following simultaneous incubation may be 
attributable to the fact that these antibodies display co-operative binding when co-
incubated, a phenomenon described in the characterisation studies (section 2.5). 
3.6.3.1.3 Effect of Incubation Time on Assay 
Fig. 3.8 shows the time course of binding in the IRMA for each concentration of 
free a-subunit studied when the incubation was performed at room temperature. 
Although binding at all concentrations of free a-subunit increased gradually with 
time, there was no meaningful increase in specific binding due to a simultaneous 
increase in NSB. As a consequence, the calculated detection limits and sensitivity 
of the assay did not increase with increasing incubation time (Table 3.5). Although 
an incubation time of 2 h showed a lower z-value, there was no effective change in 
the sensitivity of the assay. A 2 h incubation was found to be the most practical and 
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Table 3.4 Comparison of binding between simultaneous and sequential incubations 




















(1) z = 55 
(2) z = 0.82 















Free a-subunit standard concentrations (ng/ml) 
(1) vs (2) p = 0.03 
Figure 3.7 Dose response curves of the IRMA after simultaneous and sequential 














Incubation time (h) 
Figure 3.8 Time course of binding for IRMA when increasing concentrations of 
the a-subunit standard were incubated with biotinylated and 
radiolabelled antibodies at room temperature (* concentration of a-
subunit standards in ng/ml). 
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(1) z = 67.1 
(2) z = 7.8 
(3) z = 32.7 
(4) z = 19.5 
(5) z = 11.7 
* indicates the incubation time giving the best sensitivity. 
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was therefore selected for routine use. 
The amount of specifically bound radioactivity in an IRMA is determined by both 
the rate of reaction of the antigen with the capture antibody and the rate of 
dissociation of the labelled antibody-antigen complex. The reaction with capture 
antibody is generally fast owing to its presence in large excess. The possibility that 
during the reaction the labelled antibody complex may dissociate from the capture 
antibody is minimal since most antibody-antigen systems are known to have'negligible 
dissociation over a 4 h period at room temperature (Hales and Woodhead, 1980). 
The short incubation time necessary for the IRMA described here is therefore most 
likely due to a combination of the use of biotinylated capture antibody in excess and 
the stability of the biotinylated antibody-antigen-radiolabelled antibody complex. 
3.6.3.1.4 Effect of Sample Volume on Assay Sensitivity 
Table 3.6 shows both specific and non-specific binding when increasing sample 
volumes of free a-subunit standard (ranging from 0.025 - 0.2 ng/ml) were assayed. 
Neither assay binding nor sensitivity changed with increasing sample volume. 
Although an increase in sample volume would be expected to result in increased 
binding, no change in binding was observed. A possible explanation for this may be 
that an increase in sample volume changes the capture antibody concentration 
required for optimal binding thereby resulting in no effective change in binding (see 
section 3.3.2.3.2). 
3.6.3.1.5 Effect of Washing on Binding, Precision and Sensitivity 
The lowest concentration of free a-subunit detected after each successive wash of 
the bead is shown in Table 3.7. Assay sensitivity and NSB improved with two washes 
of the bead compared to one wash but no significant increase in specific binding, at 
any free a-subunit concentration was shown. 
There was however an improvement in the precision of measurement of 
quadruplicate samples at free a-subunit standard concentrations _>_0.2 ng/ml but no 
improvement in the precision of quadruplicates at low standard concentrations with 
further washing (Table 3.8). The coefficients of variation of quadruplicates were 
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(1) z = 2.5 
(2) z = 3.4 
(3) z = 3.4 
(4) z = 2.4 
* indicates the lowest standard concentration of free a-subunit in each incubation 
volume giving a sensitivity score or z value >2. 
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(1) z - 3.6 
(2) z = 2.9 
(3) z = 2.1 
* indicates the lowest concentration of a-subunit standard after each successive wash 
giving a sensitivity score of z > 2 
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Table 3.8 Percentage coefficient of variation in measuring free a-subunit in 
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> 10% at standard concentrations < 0.2 ng/ml even after 3 washes, demonstrating 
the lack of precision when measuring free a-subunit concentrations < 0.2 ng/ml. The 
minimal advantages offered by a third wash did not justify the additional procedure. 
The solid-phase was washed twice to minimise NSB to undetectable levels, thereby 
enhancing sensitivity of the assay. The lack of precision in measuring free a-subunit 
at low standard concentrations may be due to the fact that the amount of 
radioactivity detected at these concentrations is low and thus small differences in 
the cpm of quadruplicate samples can result in a high %CV. 
3.6.3.2 Characteristics of the IRMA 
3.6.3.2.1 Dose Response Curve 
A dose response curve relating bound radioactivity to free a-subunit concentration 
is shown in Fig. 3.9. Binding of the [125I]-labelled antibody increased proportionally 
with increasing concentrations of free a-subunit standard over a wide working range 
(0.05 to 32 ng/ml) with a limit of detection as low as 0.05 ng/ml of free a-subunit. 
The assay shows no evidence of the 'high dose hook' phenomenon, where a 
paradoxical fall in binding at very high antigen doses often occurs. This may be due 
to the fact that the capture antibody (biotinylated antibody 75) was used at an 
optimal concentration and very high levels of a-subunit were not measured. 
3.6.3.2.2 Sensitivity and Precision 
As shown previously (3.6.3.1), the assay sensitivity for free a-subunit under optimal 
assay conditions was as low as 0.05 ng/ml. A precision dose profile demonstrating 
intra-assay variation is shown in Fig 3.10. The intra-assay coefficient of variation 
under optimal assay conditions was < 10% at free a-subunit concentrations ranging 
between 0.2 - 32 ng/ml. The inter-assay coefficient of variation over the 
concentration range of 0.4 to 32 ng/ml was < 10% (results not shown). 
The sensitivity of the IRMA for the free a-subunit may be a result of the use of 
excess capture antibody which ensures optimal binding of antigen. Since the two 
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Figure 3.10 Precision dose profile of IRMA after assay of a-subunit 
standards. 
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should have a greater sensitivity, with almost all of the antigen reacting with both 
antibodies. 
3.6.3.2.3 Working Range 
A graph of expected versus measured serum free a-subunit concentrations in the 
range 0.03 - 32 ng/ml obtained by dilution is shown in Fig. 3.11. The levels of free 
a-subunit after dilution of the serum with horse serum were in good agreement with 
the expected values (slope 1.016 with a correlation coefficient of 0.9989). The optimal 
working range for the measurement of free a-subunit in serum was similar to that of 
the standards in the assay and extended over almost three orders of magnitude. 
Identification of the working range is important to ensure assay reliability, especially 
when choosing the appropriate dilution for samples with high free a-subunit 
concentrations. 
3.6.3.2.4 Assay Specificity 
Fig. 3.12 illustrates the percentage cross-reactivity of the glycoprotein hormone 
standard preparations in the IRMA. 
Chromatography of the FSH standard (Fig. 3.13) demonstrated the presence of 
significant contamination of the preparation with the free a-subunit which was 
responsible for about 40 - 50% of the immunoactivity. Some cross-reaction of intact 
FSH in the free a-subunit IRMA was also observed. The percentage cross-reactions 
after chromatography of the FSH standard preparation are shown in Table 3.9. 
The IRMA described for the free a-subunit shows minimal cross-reaction with the 
intact glycoprotein hormones or the free 3-subunit of hCG. This degree of specificity 
is attributed to the use of two monoclonal antibodies which recognise distinct sites 
on the antigen in a two-site binding format. In this way it is possible to trap and 
quantify a specific molecule. This is supported by the fact that when studied 
individually, the two selected monoclonal antibodies showed some cross-reaction with 
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Figure 3.12 Dose response curves for IRMA showing cross-reaction of the related 







Figure 3.13 Sephadex G100 chromatography of FSH standard (2nd IRP 78/549). 
Standard (1.0 ml) was subjected to gel filtration on a column of 
Sephadex G100 equilibrated with phosphate buffer (0.067 mol/l, pH 
7.4) and calibrated with [125I] free a-subunit and [125I]FSH. Dextran 
blue was used to determine the void volume (V0). The column was 
diluted with the same buffer at a downward flow rate of 8 ml/h and 
fractions of 1.1 ml collected. All fractions were assayed for FSH by 
RIA and for free a-subunit by the IRMA. The solid line represents 
FSH immunoactivity and the broken line free a-subunit 
immunoactivity in the fractions collected. Chromatography of the 
FSH standard revealed the presence of free a-subunit contamination 
in the preparation and some cross-reactivity of intact FSH in the 





Table 3.9 Percentage cross-reaction of free J3-subunit of hCG and related 
glycoprotein hormones (LH, FSH, TSH and hCG) in the IRMA after 
purification of FSH standard. 
glycoprotein 













Using two monoclonal antibodies, one biotinylated as the capture antibody (75) and 
the other radiolabeled as the detection antibody (71), and polystyrene beads coated 
with biotin and avidin as a solid-phase separation system, an IRMA for the 
measurement of free a-subunit of hCG was developed. 
Optimisation of the IRMA demonstrated that the use of horse serum as an assay 
diluent, the simultaneous incubation of assay reagents and two washes of the bead 
improved assay performance. On the other hand, longer incubation times and 
increased sample volumes did not have any advantage. 
The assay was found to be specific for the free a-subunit and sensitive to levels of 
0.05 ng/ml. The inter- and intra-assay CVs of the IRMA were < 10% at a-subunit 
concentrations ranging between 0.4 and 32 ng/ml. The optimal working range of the 




MEASUREMENT OF THE FREE ALPHA-SUBUNIT OF HCG IN 
GESTATIONAL TROPHOBLASTIC DISEASE 
Medical theory is truly useful, only when its practical results are beneficial. To 
judge correctly of these results, we must have recourse to the phenomena 
presented to clinical observers. It is by inductive reasoning thus experimentally 
obtained, that we can be prepared to detect the fallacy of each protean 
medical theory, whose shadowy being might long elude any other species of 
investigation. 
Alexander M'Call [early 19th Century] 
4.1 INTRODUCTION 
As mentioned in the introduction to this thesis, several workers have suggested that 
serial measurement of the serum free a-subunit of hCG may be useful in the 
diagnosis and treatment of patients with gestational trophoblastic disease (GTD) 
[Dawood et al, 1977; Gaspard et al., 1977; Quigley et al, 1980a and b]. Consequently, 
this study was undertaken, to determine the levels of free a-subunit, using the IRMA 
described previously (chapter 3) in patients with GTD both at presentation and 
during the course of treatment. 
In addition to establishing the diagnosis of GTD, there are several crucial clinical 
decisions with regard to the treatment of these patients. Because there are both 
benign and malignant forms of the disease, it is essential that this distinction be 
made as early as possible to allow for optimal therapy. It is also important to monitor 
closely the response to treatment because the objective of therapy is to remove all 
tumour cells as quickly as possible. Thus in the studies which follow, the clinical 
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utility of free a-subunit measurement is assessed with these objectives in mind. Since 
BhCG is widely accepted as the tumour marker for the diagnosis and management 
of patients with GTD, the levels of free a-subunit are also compared to those of 
BhCG, as measured by the 6RIA (Vaitukaitis et al., 1972). 
4.2 PATIENTS AND METHODS 
4.2.1 Patients 
Sixty one patients (fifty six Blacks and five Indians) ranging in age from 16 - 50 
years, with histologically proven GTD were included in the study. The selection was 
based on the patient having a high serum BhCG level (> 10 000 IU/1) at presentation 
and an adequate serial follow-up. Thirty four patients had molar disease and twenty 
seven choriocarcinoma. Of the patients with molar disease, twenty two were found 
to have benign molar disease (BMD) characterised by a rapid decline in BhCG levels 
following treatment, and twelve had persistent molar disease (PMD, metastasizing or 
invasive moles) characterised by a more gradual decline or a rise in serum 3hCG 
levels following treatment as assessed at 6 - 8 weeks post-evacuation. Of the patients 
with choriocarcinoma, one had recurrence of the disease. 
All patients with molar disease were treated initially by evacuation of the uterus. 
Patients subsequently classified as having BMD received no further therapy while 
those with PMD and those with choriocarcinoma were treated with cytotoxic 
chemotherapy. These patients were divided into three groups for the purpose of 
optimising treatment. The low risk group, consisting of patients with PMD, received 
several courses of standard doses of vincristine and methotrexate. The medium risk 
group comprised patients with choriocarcinoma whose disease either followed a term 
pregnancy, was diagnosed four months following an interrupted pregnancy or who at 
presentation had a GhCG level of >40 000 IU/7. These patients were treated with 
several courses of chemotherapy, which included cis-platinum in addition to 
methotrexate and vincristine. The high risk group comprised patients in whom the 
above treatment had failed or who had brain or liver metastases. Chemotherapy 
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given to these patients included atoposide VP 16 in addition to the other agents. 
Treatment regimes were individualized, but in general each patient received a course 
of cytotoxic therapy at 3 weekly intervals while circulating serum BhCG persisted. 
Therapeutic success was assumed when serum BhCG was no longer detectable. 
4.2.2 Blood Sampling 
Blood was taken from each patient before therapy was initiated, at weekly intervals 
during therapy and weekly for several weeks after its cessation. After collection, 
blood was separated and the serum stored at -20 ° C until assay. The blood samples 
analysed were those submitted to the laboratory for routine BhCG estimation. 
4.2.3 Assays 
Serum BhCG was measured using the Amerlex BRIA kit (Amersham); this assay 
utilises hCG standards calibrated against the 2nd International Standard (2IS). 
Thereafter, the remaining serum was stored at -20 °C until assay in the free a-
subunit IRMA described in the previous chapter. Samples from individual patients 
were assayed singly and in the same batch. 
4.2.4 Analysis of Data 
For purposes of analysis, patients were divided into 3 subgroups: BMD, PMD and 
choriocarcinoma. Where appropriate, patients were divided more broadly on the 
basis of benign or malignant (PMD and choriocarcinoma) disease. In addition to 
assessing the serum concentrations of free a-subunit and BhCG in the various 
subgroups before and during therapy, the relationship between these two components 
was also investigated by calculating the percentage free a-subunit to BhCG molar 
ratio before and during therapy. For this purpose the molecular weights of free a-
subunit and hCG were taken as 15 000 and 38 000 daltons (Bellisario et al., 1973, 
Hussa, 1981), respectively; the BhCG value measured was assumed to represent 
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essentially intact hCG. Since the IU (2IS) = 2.07 IU (1st IRP), and the biological 
activity of the 1st IRP is 9.29 IU/jug or 9.29 mlU/ng, 
1 IU// (2IS) = 2.07 mlU/ml (1st IRP) 
9.29 mlU/ng (1st IRP) 
= 0.22 ng/ml 
The %a/BhCG molar ratio was calculated as follows: 
[free a-subunit] ng/ml 
[BhCG] IU// 
[free a-subunit] ng/ml 
[BhCG] x 0.22 ng/ml 
converting to %molar ratio 
[free a-subunit] / 15 000 x 100 nmol/ml 
[BhCG] / 38 000 nmol/ml 
= [free a-subunit] x 1152 
[BhCG] 
4.2.4.1 Before Treatment 
The pretreatment serum concentrations of free a-subunit and BhCG in each of the 
3 subgroups and the benign and malignant groups were compared directly as well 
as by calculation of the percentage free a-subunit to BhCG (%a/BhCG) molar ratios. 
4.2.4.2 Response to Therapy 
4.2.4.2.1 Free a-subunit and BhCG Concentrations 
The concentrations of free a-subunit and BhCG and the %a/BhCG molar ratios in 
patients with BMD and PMD were compared at each week following evacuation of 
the mole. The regression of free a-subunit and BhCG after evacuation in BMD and 
PMD and during chemotherapy in choriocarcinoma, was also assessed by expressing 
these concentrations as a percentage of the free a-subunit and BhCG level at 
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presentation. 
4.2.4.2.2 Disappearance Time 
The average time in weeks after treatment for the free a-subunit and BhCG levels 
to reach normal levels of ^0.6 ng/ml (Norman et al., 1987) and <4 IU// (Vaitukaitis 
et al., 1972), respectively, was determined for each subgroup of patients and 
comparisons made between each group. Differences in the disappearance time 
between free a-subunit and BhCG in each of the subgroups were also determined. 
4.2.4.2.3 Free a-subunit Concentrations at Undetectable BhCG Levels 
The free a-subunit concentrations in patients who were successfully treated (BhCG 
<4 IU//, as defined in section 4.2.1) were assessed in each GTD patient. 
4.2.4.3 Case Reports 
Two patients who appeared to have unusual patterns of secretion of free a-subunit 
were studied in detail. The first of these patients (Patient A) had PMD, while the 
second (Patient B) had recurrence of choriocarcinoma. 
4.2.5 Statistical Analysis 
All values were expressed as mean ± S.E.M. The statistical analyses of unpaired 
data were based on non-parametric procedures when the data studied were not 
normally distributed. The statistical significance of differences between the means 
of the two groups was tested by the Mann-Whitney procedure; probability values 
were taken from two-tailed tables and only values of p <0.05 were considered 
significant. When multiple (> 2) comparisons were made, the Kruskall-Wallis analysis 
of variance on ranks was used to determine whether there were any significant 
differences between the groups studied. If a significant difference was found, pairwise 
comparisons were then made using the Mann-Whitney test with Bonferroni 
adjustments. The significance level in this case was adjusted by dividing the p value 
of 0.05 by the number of comparisons made. 
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The paired t-test was applied when data were normally distributed and used to 
determine the significance of the differences between pairs of data when samples 
were tested for two variables. 
4,3 RESULTS 
4.3.1 Before Treatment 
The reference range for serum free a-subunit in pre-menopausal females is 0.05 -
0.6 ng/ml (Norman et al., 1987). At presentation, all women with GTD had 
concentrations of free a-subunit above the reference range (mean 18.6 +_ 1.2 S.E.M.; 
range 1.5 - 37.7 ng/ml). Table 4.1 shows the serum concentrations of free a-subunit 
and BhCG, and the %a/BhCG molar ratios, before treatment in each of the 3 
subgroups and in patients with malignant disease. The free a-subunit levels in 
patients with BMD were similar to those in both PMD and choriocarcinoma when 
compared as individual groups or together as malignant disease. However, the free 
a-subunit levels in patients with PMD were found to be significantly higher (p = 
0.012) than in patients with choriocarcinoma. There were no significant differences 
in BhCG levels between the different subgroups, or between the benign and 
malignant groups. Similarly, no significant differences were found in the %a/BhCG 
molar ratios. 
4.3.2 Response to Therapy 
4.3.2.1 Free a-subunit and BhCG Concentrations 
The serum levels of free a-subunit in almost all patients with GTD decreased 
progressively but erratically during treatment and roughly parallelled serum 
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Table 4.1 Free a-subunit and BhCG levels and percentage free a-subunit to BhCG molar ratios in patients with GTD before treatment. 
Patients free a-subunit (ng/ml) 
mean ± S.E.M. range 
BMD (n=18) 19.9 ±2 .3 1.5-36.0 
PMD (n=12) 22.2 ± 2.60) 2.1 - 37.7 
choriocarcinoma (n = 22) 15.6 ± 1.3(2) 1.9 - 28.9 
malignant disease (n = 34) 17.9 ± 1.4 1.9 - 37.7 
all patients (n = 52) 18.6 ± 1.2 1.5-37.7 
BhCG (IV/I) 
mean ± S.E.M. range 
294489 ± 106546 18600 - 2040000 
519063 ± 117223 23250 - 1289000 
302607 ± 58866 11100 - 1010000 
379003 ± 58032 11100 - 1289000 
349748 ± 52596 11100 - 2040000 
%a/BhCG molar ratio 
mean ± S.E.M. range 
0.21 ± 0.03 0.001 - 0.42 
0.09 ± 0.02 0.03 - 0.21 
0.21 ± 0.05 0.01 - 1.2 
0.10 ± 0.04 0.01 - 1.2 
0.02 ± 0.03 0.001 - 1.2 
molecular weights of free a-subunit and BhCG taken as 15 000 and 38 000 daltons, respectively. 
(1) vs (2) p = 0.012* 
* Mann-Whitney test with Bonferroni adjustment (significance level p <0.0167) 
concentrations of BhCG. 
The typical decreases in serum BhCG and free a-subunit concentrations following 
treatment in patients with BMD, PMD and choriocarcinoma are illustrated in Figs. 
4.1, 4.2 and 4.3, respectively. In patients with BMD both parameters decreased 
rapidly following evacuation until undetectable levels were achieved. A similar rapid 
decrease was demonstrated in patients with PMD in the first two weeks following 
evacuation, but thereafter the decrease was more gradual. The mean serum 
concentrations of free a-subunit and BhCG were therefore not different in these 
groups of patients at the first week post-evacuation (p >0.05), but thereafter (until 
the eighth week following therapy) the levels of both free a-subunit and BhCG were 
significantly higher in patients with PMD (p <0.05) as shown in Table 4.2. In patients 
with choriocarcinoma, both free a-subunit and BhCG concentrations decreased 
gradually but erratically during cytotoxic therapy. 
In patients with BMD and PMD, the %a/BhCG molar ratio demonstrated a 
progressive rise following evacuation. However, the increase in the molar ratio was 
considerably greater in patients with BMD (> 100 fold) compared to patients with 
PMD (< 10 fold); hence the ratio was significantly higher in BMD from 2 - 7 weeks 
post-evacuation (Table 4.2). In contrast, the %a/BhCG molar ratio fluctuated 
throughout the course of treatment in patients with choriocarcinoma. 
Figures 4.4, 4.5 and 4.6 illustrate the patterns of change in serum free a-subunit and 
BhCG, when the levels at each week post-evacuation in BMD and PMD, and each 
week of chemotherapy in choriocarcinoma, respectively, were expressed as a 
percentage of the values at presentation. In all 3 subgroups, BhCG cleared far more 
rapidly than free a-subunit. The percentage decrease in free a-subunit and BhCG 
levels relative to the level at presentation was similar in BMD and PMD in the first 
week following treatment but differed significantly (p <0.05) thereafter and until 8 
weeks post-evacuation (results not shown). 
4.3.2.2 Disappearance Time 
The time taken for the disappearance of both free a-subunit and BhCG was 
102 
100000 
</> Evacuation of mole 
-100 
•»., 
/ %a//3hCG molar ratio 
/3hCG 
Free a-subunit 
i i i i i 
2 4 6 8 10 









Figure 4.1 Serum free a-subunit and BhCG concentrations, and the %a/BhCG 
molar ratio in a typical patient with BMD treated by evacuation of 
the mole. 
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Figure 4.2 Serum free a-subunit and fihCG concentrations, and the %a/3hCG 
molar ratio in a typical patient with PMD treated by evacuation of 
mole and cytotoxics. 
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Figure 4.3 Serum free a-subunit and BhCG concentrations, and the %a/6hCG 
molar ratio in a patient with choriocarcinoma treated with cytotoxics. 
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mean ± S.E.M 
5.2 ± 1.2 
1.8 ± 0.40 
1.4 ± 0.35 
0.89 ± 0.22 
0.82 ± 0.21 
0.89 ± 0.21 
0.37 ± 0.13 
0.28 ± 0.09 
concentration (ng/ 
PMD 
mean ± S.E.M 
7.1 ± 1.3 
4.2 ± 0.74 
4.9 ± 1.1 
4.5 ± 0.85 
3.1 ± 0.59 
3.2 ± 0.75 
3.3 ± 0.76 














mean ± S.E.M 
18949 ± 8900 
1696 ± 440 
788 ± 312 
307 ± 177 
541 ± 403 
412 ± 283 
19 ± 5.0 
52 ± 39 
concentration (IU/7) 
PMD 
mean ± S.E.M 
23822 ± 7824 
9780 ± 3252 
10991 ± 4649 
11191 ± 3084 
8341 ± 3472 
7521 ± 3769 
6069 ± 3617 











%a /6hCG molar ratio 
BMD 
mean±S.E.M 
0.09 ± 0.22 
2.0 ± 0.49 
4.7 ± 1.3 
1.3 ± 2.9 
16 ± 5.1 
45 ± 29 
38 ± 16 
25 ± 8.4 
PMD 
mean±S.E.M 
0.66 ± 0.12 
0.92 ± 0.13 
1.0 ± 0.15 
1.4 ± 0.65 
1.2 ± 0.33 
1.5 ± 0.37 
2.7 ± 1.0 
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Figure 4.4 Post-evacuation disappearance of serum free a-subunit and BhCG in 
patients with BMD. 
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Figure 4.5 Post-evacuation disappearance of serum free a-subunit and 6hCG in 
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Figure 4.6 Disappearance of free a-subunit and GhCG during chemotherapy in 
patients with choriocarcinoma. 
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significantly shorter in BMD than in either PMD (p = 0.006) or malignant disease 
(PMD and choriocarcinoma; p <0.02), but not significantly different to 
choriocarcinoma alone as shown in Table 4.3. In addition, the disappearance of free 
a-subunit was significantly earlier than that of BhCG in each subgroup tested. 
4.3.3 Free a-subunit Concentrations at Undetectable BhCG Levels 
The free a-subunit levels in patients with GTD in whom undetectable BhCG levels 
had been achieved following treatment were all within the normal reference range 
for pre-menopausal females except one patient with PMD who had unusual levels of 
free a-subunit, as described in detail in section 4.3.4. 
4.3.4 Case Reports 
Fig. 4.7 demonstrates the changes in BhCG and free a-subunit levels and the 
%a/BhCG molar ratios in a patient with PMD (Patient A) during the course of the 
disease. The free a-subunit levels remained unchanged during treatment although 
BhCG concentrations decreased to undetectable levels. The %a/BhCG molar ratios 
therefore increased rapidly and were very high when BhCG concentration was 7 IU//. 
A rise in the BhCG level (6 IU//) after achieving an undetectable level, was noted 
in a serum sample taken 4 weeks later (not shown in illustration). 
Fig. 4.8 illustrates the changes in free a-subunit and BhCG levels, and the %a/BhCG 
molar ratios in a patient with recurrent choriocarcinoma (Patient B). Two weeks after 
detection of recurrence (by a rising BhCG level), the free a-subunit levels were 
increased above normal levels. This was reflected by a %a/BhCG molar ratio of 45, 
which was higher (mean + 2 SD) than the mean pretreatment ratio in all GTD 
patients studied. The %a/BhCG ratio fluctuated initially and then decreased 
gradually, but erratically during the course of the disease. 
110 
Table 4.3 Disappearance time of free a-subunit and BhCG (in weeks) in GTD patients after treatment. 
Patients 
benign moles (n = 8) 
persistent moles (n = 6) 
choriocarcinoma (n = 4) 
malignant disease (n = 10) 
free 
mean ± S.E.M. 
5.9 ± 0.93(1) 
14.1 ± 2.2(2) 
10.4 ± 1.6<3) 




2.8 - 10.0 
5.6 - 21.0 
7.1 - 14.6 
5.6 - 21.0 
BhCG 
mean ± S.E.M. 
12.2 ± 1.4(5) 
21.1 ± 2.0(6) 
15.9 ± 3.0(7) 
19.0 ± 1.8(8) 
range 
8.0 - 17.9 
14.9 - 27.7 
10.7 - 23.7 
10.7 - 27.7 
(1) vs (2) p = 0.006* (1) vs (5) p = 0.007** 
(1) vs (4) p < 0.02 (2) vs (6) p - 0.015** 
(5) vs (6) p = 0.006* (3) vs (7) p - 0.033** 
(5) vs (8) p < 0.02 
* Mann-Whitney test with Bonferroni adjustments (significance level p < 0.0167) 
**Paired t-test (significance level p <0.05) 
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Figure 4.8 Serum free a-subunit and BhCG concentrations, and %a/BhCG 




There has been a great deal of controversy in the literature regarding the usefulness 
of routine free a-subunit estimations in the management of GTD. Although many 
workers have found free a-subunit measurement to be useful in the diagnosis and 
treatment of this disease, especially in high-risk patients (Schreiber et al., 1976; 
Dawood et al, 1977; Gaspard et al, 1977; Nishimura et al, 1979; Quigley et al, 1980 
a and b), others have found little use for free a-subunit estimations in these patients 
(Bagshawe 1980; 1984; Kohorn et al, 1981). In these studies, however, polyclonal 
antibodies were used to measure free a-subunit and therefore could not be expected 
to have the sensitivity or specificity of the assay used in the present study. Hence, 
the true value of free a-subunit estimation in the management of GTD cannot be 
assessed from these earlier data. In the current study, a highly sensitive IRMA using 
monoclonal antibodies specific for the free a-subunit has been developed which has 
allowed the measurement of low levels of free a-subunit in the presence of high 
concentrations of intact hCG as found in trophoblastic disease. This specific IRMA 
was used to re-examine and evaluate the clinical usefulness of free a-subunit 
measurements in the diagnosis and the monitoring of tumour response to therapy 
in patients with GTD. 
At presentation, the levels of free a-subunit in all patients in this study were 
considerably higher than the reference range for normal premenopausal females as 
determined by Norman et al. (1987) using a similar assay. However there would not 
appear to be any advantage in the measurement of free a-subunit for the initial 
diagnosis of GTD because the relative increase in this component is not as marked 
as that of RhCG. Furthermore, measurement of free a-subunit was of no value in 
differentiating between patients with benign and malignant disease at presentation, 
supporting an observation made by Hay (1988) who used a monoclonal-based IRMA 
to measure free a-subunit. 
During the follow-up of patients with molar disease, however, both free a-subunit 
and BhCG concentrations were found to be significantly increased within 2 weeks 
of evacuation in PMD compared to BMD. In addition, the %a/3hCG molar ratios 
were significantly higher in patients with BMD than in those with PMD. Since 
114 
trophoblastic tumours display heterogeneity in tumour size, the free a-subunit and 
BhCG concentrations were also expressed as a percentage of the levels at 
presentation. Similar differences between benign and malignant disease were 
observed and confirmed the above finding. Currently patients with molar disease are 
assessed at 6-8 weeks post-evacuation and grouped according to 3hCG 
concentrations. Results from this study show that differences in subgroups of patients 
were already apparent at 2 weeks, potentially allowing for an earlier distinction 
between BMD and PMD. Furthermore, the molar ratios may also be useful to 
differentiate the two subgroups. 
Although BhCG was present in much higher concentrations, its rate of disappearance 
was found to be faster than that of the free a-subunit in all groups of patients. This 
may be explained by either increased production of free a-subunit in relation to hCG 
by tumour tissue or by the relatively faster clearance of hCG. In BMD where it can 
be assumed that essentially all tumour tissue has been removed at surgery, it would 
appear that the observed rates of disappearance are more likely due to the enhanced 
clearance of hCG relative to the free a-subunit. The relative clearance rates of both 
free a-subunit and hCG in GTD in this study differ considerably from published data 
on half-life times (t1/2) of hCG and the free a-subunit (Wehman and Nisula, 1979; 
1981). These workers administered highly purified preparations of intact hCG and 
free a-subunit to normal subjects and found that the plasma t1/2 of free a-subunit of 
hCG was significantly faster than that "of intact hCG (1.27 vs 35.6 h). A possible 
explanation for the observed difference in clearance rates in GTD may be due to the 
presence of alternative forms of hCG and free a-subunit which have been described 
in some patients (Amr et al., 1983; 1984). Heterogeneity in the carbohydrate content 
is believed to significantly influence the survival time in blood (Amr et al., 1984). 
Desialylated forms of hCG which are rapidly cleared from the circulation have been 
found in the urine of patients with choriocarcinoma but are not present in normal 
pregnancy (Amr et al., 1985). In addition, the secretion of large forms of free a-
subunit has been observed in cultured human malignant trophoblasts (Hussa, 1977). 
These forms have a prolonged plasma half-life relative to the a-subunit found in 
normal pregnancy. 
In patients with GTD, successful therapy is assumed when the concentration of BhCG 
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reaches normal or undetectable levels. In all 3 groups of patients normal levels of 
free a-subunit were achieved earlier than BhCG despite its slower clearance. 
Although this most likely relates to the lower initial concentrations of free a-subunit 
compared to BhCG, free a-subunit estimation may therefore also be useful for the 
early identification of cure or remission in patients with GTD. 
In the follow-up of two patients with malignant disease in detail, an unusual pattern 
of secretion of a-subunit and BhCG was noted. The preferential secretion of a-
subunit has also been demonstrated by Dawood et al. (1977) in two patients with 
choriocarcinoma whose a-subunit levels increased while hCG declined or were 
absent. Since the intact hCG levels were low or undetectable, the a-subunit measured 
was more likely to be free a-subunit and thus the persistence of the disease might 
have been missed if only the intact hCG levels were measured. It may therefore be 
necessary to measure both free a-subunit and BhCG in the management of patients 
with GTD. 
The preliminary data from this study indicate that the measurement of free a-subunit 
together with that of BhCG may have an additional usefulness in the earlier 
identification of patients with malignant forms of GTD. In patients with molar 
disease, the use of prophylactic chemotherapy at the time of evacuation has met 
with little enthusiasm, since 80 - 85% of patients with BMD undergo spontaneous 
remission after evacuation (Khazaeli et al., 1986). Differentiation between benign and 
persistent disease, as early as possible, is important to allow earlier chemotherapeutic 
intervention and possible prevention of high risk disease (cerebral and liver 
metastases). In addition, because of its earlier disappearance, measurement of free 
a-subunit may also be useful in the monitoring of tumour response to therapy. Since 
tumours may secrete free a-subunit preferentially, it is important to measure both the 
free a-subunit and BhCG. Although the results obtained here are promising, this 
study was of a retrospective nature and included only a modest number of patients. 
A prospective study, with a larger number of patients and good follow-up would allow 
a thorough examination of free a-subunit levels in GTD and may lead to 
confirmation of these preliminary results. 
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4.5 SUMMARY 
Increased levels of free a-subunit were found in the sera of all patients with GTD. 
The pre-treatment free a-subunit levels were significantly higher in PMD than in 
choriocarcinoma while no significant differences in the BhCG and %a/BhCG molar 
ratio within the subgroups were noted. 
After evacuation and during chemotherapy the free a-subunit levels generally 
decreased in parallel with BhCG levels. The free a-subunit and BhCG concentrations 
in patients with molar disease, were found to be significantly higher from 2 - 8 weeks 
post-evacuation in PMD when compared with BMD. The %a/BhCG molar ratios at 
each week following evacuation were significantly higher between 2 and 7 weeks post-
evacuation in BMD. The disappearance of free a-subunit and BhCG, expressed as a 
percentage of the initial levels, showed similar differences. However, the rate of 
disappearance of BhCG was faster than that of free a-subunit. The disappearance 
time of both free a-subunit and BhCG, in weeks, was significantly shorter in BMD 
than in PMD or malignant disease while the free a-subunit disappeared before BhCG 
in each subgroup. 
After treatment, detectable free a-subunit levels were found in patients who were 
cured or in remission; these concentrations were within the reference range for pre-
menopausal females. In one patient with recurrence of disease, the %a/BhCG molar 
ratio increased initially due to a paradoxical secretion of free a-subunit and BhCG. 
Another patient presenting with PMD was found to have an unchanged serum free 
a-subunit level throughout the course of the disease. 
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SUMMARY AND CONCLUSION 
The great art consists in devising decisive experiments, leaving no place to the 
imagination of the observer. Imagination is needed to give wings to thought at the 
beginning of experimental investigations on any given subject. Wlien, however the time 
has come to conclude, and to interpret the facts derived from observations, imagination 
must submit to the factual results of the experiments. 
Louis Pasteur [ 1822 - 1895] 
The mouse hybridoma technique was successfully used to culture two clones secreting 
monoclonal antibodies to the free a-subunit of hCG. On subtyping, the antibodies 
designated 71 and 75 were found to be of the IgGl subclass. Both antibodies 71 and 
75 were very specific for the free a-subunit but showed comparatively low affinities 
for the molecule, with dissociation constants of 0.92 x 10'8 and 4.08 x 108 mol/7, 
respectively. Each antibody was shown to recognise two distinct epitopes on the free 
a-subunit molecule. In addition, the two antibodies 71 and 75 displayed cooperativity 
in binding to the free a-subunit when incubated simultaneously. 
Using these two antibodies, one biotinylated as the capture antibody (75) and the 
other radiolabelled as the detection antibody (71), and polystyrene beads coated with 
avidin as a solid-phase separation system, an IRMA for the measurement of the free 
a-subunit of hCG was developed. The assay was found to be simple to perform, 
specific for the free a-subunit, sensitive to levels as low as 0.05 ng/ml and precise 
at a-subunit concentrations ranging between 0.2 - 32 ng/ml. 
The assay was used to assess the usefulness of free a-subunit measurements in the 
diagnosis and management of patients with GTD. The levels of free a-subunit in 
these patients were found to be increased but were of no additional value to BhCG 
in either the initial diagnosis or in differentiating between benign and malignant 
disease. After evacuation and during chemotherapy, the free a-subunit levels 
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decreased and generally followed the same pattern of change as seen in 3hCG. The 
disappearance time of free a-subunit was shorter than that of BhCG. This important 
finding may allow an earlier identification of patients with persistent disease and may 
also play a role in the earlier detection of tumour response to chemotherapy. On the 
other hand, the rate of disappearance of BhCG was found to be faster than that of 
the free a-subunit in all groups of patients. This unexpected observation may be 
explained by the possible presence of larger forms of free a-subunit or lower 
molecular weight desialylated forms of hCG in GTD. Because of the retrospective 
nature of this study and modest patient numbers the value of free a-subunit 
estimation in the management of GTD is still uncertain at this stage. A prospective 
study, with a larger patient population may confirm these preliminary results. 
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